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ABSTRACT 
Gregory Randall Wagner 
 
IDENTIFICATION AND CHARACTERIZATION OF ALTERED 
MITOCHONDRIAL PROTEIN ACETYLATION IN FRIEDREICH’S ATAXIA 
CARDIOMYOPATHY 
 
Friedreich’s Ataxia (FRDA) is a rare and poorly understood autosomal 
recessive disease caused by a pathological deficiency of the mitochondrial 
protein frataxin. Patients suffer neurodegeneration, ataxia, diabetes, and heart 
failure. In an effort to understand the mechanisms of heart failure in FRDA, we 
investigated the role of the protein modification acetylation, which is highly 
abundant on mitochondrial proteins and has been implicated in regulating 
intermediary metabolism. Using mouse models of FRDA, we found that cardiac 
frataxin deficiency causes progressive hyperacetylation of mitochondrial proteins 
which is correlated with loss of respiratory chain subunits and an altered 
mitochondrial redox state. Mitochondrial protein hyperacetylation could be 
reversed by the mitochondria-localized deacetylase SIRT3 in vitro, suggesting a 
defect in endogenous SIRT3 activity. Consistently, frataxin-deficient cardiac 
mitochondria showed significantly decreased rates of fatty acid oxidation and 
complete oxidation to carbon dioxide. However, the degree of protein 
hyperacetylation in FRDA could not be fully explained by SIRT3 loss. Our data 
suggested that intermediary metabolites and perhaps acetyl-CoA, which is 
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required for protein acetylation, are accumulating in frataxin-deficient 
mitochondria. Upon testing the hypothesis that mitochondrial protein acetylation 
is non-enzymatic, we found that the minimal chemical conditions of the 
mitochondrial matrix are sufficient to cause widespread non-enzymatic protein 
acetylation in vitro. These data suggest that mitochondrial protein 
hyperacetylation in FRDA cardiomyopathy mediates progressive post-
translational suppression of mitochondrial oxidative pathways which is caused by 
a combination of SIRT3 deficiency and, likely, an accumulation of unoxidized 
acetyl-CoA capable of initiating non-enzymatic protein acetylation. These findings 
provide novel insight into the mechanisms underlying a poorly understood and 
fatal cardiomyopathy and highlight a fundamental biochemical mechanism that 
had been previously overlooked in biological systems.  
 
 
R. Mark Payne, M.D., Chair 
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CHAPTER I: INTRODUCTION  
The genetic and molecular basis of Friedreich’s Ataxia 
In 1863, a disease characterized by progressive neurodegeneration and 
loss of motor coordination and walking ability (ataxia) was observed in five 
patients by the German professor of pathology, Nicolaus Friedreich, and soon 
became known as Friedreich’s Ataxia (FRDA) (1). In 1996, an international team 
led by Professors Massimo Pandolfo and Michel Koenig identified the causal 
genetic defect in Friedreich’s Ataxia patients (2). Their earlier linkage analysis 
using Friedreich’s Ataxia patient samples had mapped the segregating disease 
region to a 150 kilobase fragment located on chromosome 9q13-q21.1 (3). They 
then performed an EcoR1 restriction digest mapping of the critical region and 
found that a fragment corresponding to intron 1 of the X25 gene was, on 
average, 2.5 kb larger in FRDA patients and carriers than in controls. After 
sequencing this fragment, they discovered a GAA·TTC triplet nucleotide repeat 
expansion in 98% of FRDA patients and carriers that ranged in size from 
approximately 200 to 900 repeats, while control samples contained 7 to 32 
repeats. The remaining two percent of patients were compound heterozygous for 
the GAA expansion and a point mutation in the X25 coding region. Thus, the 
international research team found that Friedreich’s Ataxia was an autosomal 
recessive disorder caused by a triplet nucleotide repeat expansion located in 
intron 1 of the X25 gene (2). This gene is now known as FXN and its protein 
product is known as Frataxin. 
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Given that the FRDA patients identified as compound heterozygous 
harbored putative loss-of-function mutations in the FXN gene, it was 
hypothesized that the other GAA-repeat containing allele generated less gene 
product through defects in either messenger RNA (mRNA) splicing or gene 
transcription. Indeed, studies soon confirmed that the GAA-repeat expansions in 
the FXN gene were associated with minimal to undetectable levels of Frataxin 
mRNA in FRDA patient tissues (2). Bidichandani, et al. determined that Frataxin 
mRNA deficiency in FRDA patients was unrelated to a splicing defect and, 
instead, was inversely related to the size of the GAA repeat expansions; the 
longer the GAA repeat, the less Frataxin mRNA generated in an in vitro 
transcription assay (4). The authors proposed several models through which the 
intronic GAA repeat tract could facilitate the formation of non-Watson-Crick base 
pairing DNA triplex structures, which could then interfere with FXN transcription. 
Additional work extended this study by demonstrating that the GAA repeats do 
not interfere with transcription initiation, rather they impede transcriptional 
elongation. The B-triplex DNA structures likely inhibit the extension of RNA 
polymerase, resulting in less Frataxin mRNA transcript and, consequently, less 
Frataxin protein product (5). 
Although an expanded GAA repeat in intron 1 of the FXN gene is the 
primary cause of Friedreich’s Ataxia, there is substantial evidence implicating 
epigenetic silencing of the FXN locus as a secondary cause underlying impaired 
transcription of Frataxin mRNA. Saveliev, et al. found that short repeat 
expansions found in myotonic dystrophy and FRDA promote the local formation 
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of heterochromatin, reduce promoter accessibility, reduce transcription of 
engineered transgenes, and recruit heterochromatin protein 1 (HP1) (6). These 
observations indicated that the GAA expansions in FRDA likely promote 
transcriptional silencing of the FXN locus in a manner akin to position effect 
variegation where genes adjacent to heterochromatic regions become silenced. 
In support of this notion, Herman et al. demonstrated that the FXN locus in FRDA 
lymphoblast cell lines exhibits hypoacetylation on Histones 3 and 4, consistent 
with the formation of heterochromatin and transcriptional repression (7). A 
significant increase in methylation of the Frataxin promoter has also been 
observed in a large FRDA patient cohort. Furthermore, increased methylation 
was inversely correlated with Frataxin mRNA expression (8). Taken together, 
these studies indicate that triplet repeat-induced transcriptional silencing, in 
addition to transcriptional blockade induced by aberrant DNA structures, 
contributes to impaired transcription of the FXN gene. 
 
The FXN gene and the function of its gene product, Frataxin 
In humans, the FXN gene consists of 7 exons spanning an 80 kilobase 
region located on chromosome 9q21.11 (9). The FXN gene/protein is highly 
conserved throughout evolution, having homologs in chimpanzee (Pan 
troglodytes) to single-celled eukaryotes such as yeast (Schizosaccharomyces 
pombe) (Figure 1.1). Human FXN produces three transcript variants according to 
the most recent entry in the National Center for Biotechnology Information (NCBI) 
Database. The longer transcript variant (NM_000144.4) represents the canonical 
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transcript while the other variants may be artifacts and currently have unknown 
function. This translated transcript produces a 210 amino acid protein known as 
Frataxin. 
 
Figure 1.1 Frataxin protein sequence aligned and conservation. Uniprot BLAST 
protein sequence alignment for Frataxin across diverse species indicates strong 
evolutionary conservation. DROME, D. Melanogaster (Fruit Fly); BOVIN, Cow; 
CAEEL, C. elegans (roundworm).  
 
Human Frataxin is translated as a precursor polypeptide containing an N-
terminal mitochondrial targeting sequence spanning amino acids 1-41. This 
Frataxin precursor is trafficked to the mitochondrion and imported into the 
mitochondrial matrix via the import pore machinery and then processed into at 
least two different forms by the mitochondrial processing peptidases (MPPs) (10, 
11). The first processing cleavage removes the 41 amino acid mitochondrial 
targeting sequence to generate Frataxin42-210. This intermediate form is then 
further processed, removing N-terminal amino acids 42-80 to yield the mature 
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protein composed of amino acids 81-210, which resides in the mitochondrial 
matrix. Frataxin is transcribed and expressed in every type of mammalian tissue, 
but it is particularly abundant in the central nervous system, dorsal root ganglia, 
and heart (12). 
The exact biochemical function of Frataxin remains undefined. However, 
there is a consensus in the literature that Frataxin has a role in several aspects of 
mitochondrial iron homeostasis. The first functional studies in yeast indicated that 
deletion of the yeast Frataxin homolog resulted in reduced oxygen consumption 
and impaired mitochondrial oxidative phosphorylation (13). Furthermore, 
overexpression of this Frataxin homolog in a yeast strain unable to grow on iron-
deficient medium partially alleviated the growth defect, suggesting Frataxin 
functioned in iron mobilization (13). Systemic ablation of Frataxin in mice is 
incompatible with embryonic development, highlighting an essential function for 
Frataxin in mammalian systems (14). Conditional ablation of Frataxin in the heart 
and brain (Neuron Specific Enolase-Cre, NSE-Cre), or heart and skeletal muscle 
(Muscle Creatine Kinase-Cre, MCK-Cre) of mice causes degeneration of the 
dorsal root ganglia, ataxia, and deficiency of respiratory complexes I, II, and III, 
and aconitase in the heart and brain stem (15). Furthermore, there is a late onset 
accumulation of iron deposits in the myocardium in the longer-lived MCK-Cre 
animals (15). Frataxin is known to act as a citrate-dependent iron chaperone 
responsible for modulating the assembly of the labile 4Fe-4S iron-sulfur cluster of 
mitochondrial aconitase (16). Additionally, Frataxin interacts with multiple 
members of the mitochondrial iron-sulfur cluster assembly machinery including 
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the cysteine desulfurase also known as NFS1, the iron-sulfur cluster scaffold unit 
(ISCU) and ISD11, forming a 190 kDa complex (17). There is also evidence 
suggesting that the Frataxin42-210 intermediate oligomerizes to sequester intra-
mitochondrial iron (11). Together, these studies indicate that Frataxin has an 
essential role in the metabolism of iron, particularly in the proper assembly and 
function of intra-mitochondrial and, perhaps, extra-mitochondrial iron-sulfur 
cluster dependent proteins.  
 
The biochemical and molecular consequences of Frataxin deficiency  
With knowledge gained from human patients as well as animal and 
cellular models, recent investigations have uncovered a great deal of information 
toward a better understanding of the disease mechanisms underlying FRDA 
pathogenesis. Although the true function of Frataxin remains undefined, its best 
understood role is in the biosynthesis and function of mitochondrial iron-sulfur 
cluster-dependent proteins. The earliest functional studies of Frataxin deficiency 
following the identification of the causal gene defect demonstrated impaired 
activity of the iron-sulfur cluster proteins of the Electron Transport Chain (ETC) 
including Complex I, II, and III (18). This study also discovered that mitochondrial 
aconitase of the tricarboxylic acid (TCA) cycle also displayed impaired activity. 
This seminal work revealed FRDA as a mitochondrial disorder and provided the 
basis for understanding Frataxin’s role in mitochondrial iron homeostasis. In 
addition to its role in ISC assembly, Frataxin was shown to play an active role as 
a citrate-dependent iron chaperone involved in aconitase activation (16). 
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Consistent with impaired ETC activity in FRDA, phosphorus magnetic resonance 
spectroscopy studies indicated reduced ATP production in patient skeletal 
muscle and heart (19, 20). Furthermore, the level of energy deficit in the patients 
studied was strongly correlated with the degree of cardiac hypertrophy, 
highlighting the importance of impaired energy homeostasis in FRDA 
cardiomyopathy. The majority of the mitochondrial and biochemical defects 
identified in human patients have also been recapitulated in mouse models of 
FRDA (15, 21), which have provided valuable systems for testing potential 
therapeutic interventions (22, 23). 
Although ISC enzyme deficiency and consequently impaired energy 
generation is widely regarded as the major pathogenic mechanism underlying 
FRDA, there are also important arguments for disrupted mitochondrial and 
cellular iron homeostasis as late-onset factors of disease progression. Iron 
deposition in cardiomyocytes often accompanies myocardial hypertrophy in 
FRDA (24), suggesting a role for iron toxicity-mediated oxidative tissue damage. 
However, the myocardial iron-positive granules only become evident upon post-
mortem tissue analysis which limits an accurate interpretation of a role for iron 
dyshomeostasis in disease progression. A detailed analysis of the Neuron-
specific enolase (NSE) and Muscle Creatine Kinase (MCK) mouse models of 
FRDA demonstrated that cardiac hypertrophy and mitochondrial iron-sulfur 
cluster protein defects precede any evidence of myocardial iron-deposition, 
suggesting that iron accumulation may be a secondary disease phenotype (15). 
Nonetheless, the MCK mouse models do eventually develop mitochondrial iron 
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deposition along with marked rearrangement of genes involved in mitochondrial 
and cellular iron import and storage (25). Attempting to limit cardiac iron 
deposition in the MCK mouse models via a mitochondrial permeable iron chelator 
limited cardiac iron-loading and hypertrophy (22). Another study of iron chelation 
therapy in a Frataxin-knockdown cell line demonstrated an increase in aconitase 
activity as well as improvements in mitochondrial membrane potential and ATP 
production (26). Together, these studies indicate that a dysregulation of 
mitochondrial iron metabolism may ultimately be important in the progression of 
FRDA. 
An increased sensitivity to oxidative stress is also likely to contribute to 
disease progression in FRDA. Reactive oxygen species (ROS) are a 
physiological byproduct of aerobic mitochondrial respiration that, in excessive 
quantities, can cause damage to cellular macromolecules including DNA, protein, 
and lipid membranes and may ultimately lead to apoptotic cell death. Although 
healthy cells have robust mechanisms for mitigating ROS, evidence indicates 
that Frataxin-deficient cells are less capable of coping with oxidative insults (27, 
28). This increased sensitivity or lower threshold for oxidative stress may be 
causally related to disrupted iron utilization, but may also represent an 
independent factor in the disease development. Early work demonstrated that 
FRDA patient fibroblasts are hypersensitive to hydrogen peroxide and that this 
sensitivity is partially rescued through iron chelation (27). An additional 
investigation also noted that mitochondrial manganese superoxide dismutase 
(MnSOD) failed to be induced in both FRDA patient fibroblasts and in the heart of 
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mouse models (28). The increased sensitivity to ROS in FRDA has also been 
supported through studies in yeast and human lymphoblasts indicating 
impairments of the glutathione defense to ROS (29). Although there may be an 
increased vulnerability to oxidative damage due to impaired endogenous 
antioxidant defenses, research in animal models suggests that oxidative stress, 
by itself, is not a notable effect of Frataxin deficiency (30). Thus, it is important to 
distinguish between increased basal levels of oxidative stress and an increased 
sensitivity to oxidative stress, as this has been a topic of considerable 
controversy in FRDA research (30). Nevertheless, the continuous bioenergetic 
and mechanical demands of the human heart may be sufficient to exceed this 
lower threshold for oxidant stress and promote the development of cardiac 
pathology.  
Accumulating evidence suggested that Frataxin-deficient cells and tissues 
may experience impaired lipid metabolism. A recent study using Drosophila 
models of FRDA demonstrated a global accumulation of free fatty acid species 
as wells as specific accumulation of lipid droplets in glial cells (31). However, this 
study failed to distinguish between a potential impairment in lipid oxidation and 
an increase in lipid synthesis. Furthermore, a recent gene expression study of 
peripheral blood lymphocytes derived from human FRDA patients and 
heterozygous carriers for the GAA repeat expansion also provided evidence for 
rearrangements of lipid homeostasis (32). These studies emphasize that altered 
lipid biology may be a systemic factor of FRDA pathogenesis, a notion that has 
critical implications for both cardiac and mitochondrial function. An increasing 
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body of evidence generated predominantly through studies of type 2 diabetes 
indicates that there are systemic pathological consequences associated with 
impaired lipid homeostasis (33). These include widespread inflammation 
mediated by adipokines and toxic accumulation of oxidized lipid species and 
ceramides which are known to induce tissue damage and apoptosis, particularly 
in the human heart (34). The β-Oxidation of fatty acids occurs in the 
mitochondrial matrix, where it serves to generate acetyl-CoA for further oxidation 
through the TCA cycle. Fat is the predominant source of carbon fuel for the heart, 
deriving as much as much as 70% of the ATP necessary for contraction from 
fatty acid oxidation (35, 36). Importantly, a prolonged energetic shift away from 
fatty acid oxidation is a well-known characteristic of developing heart failure (37), 
suggesting that this may contribute to FRDA disease progression. Furthermore, 
impairments in fatty acid oxidation are known to occur in the skeletal muscle of 
patients with clinical evidence of respiratory chain dysfunction (38). Alternatively, 
a functional deficit of mitochondrial aconitase could promote increased 
mitochondrial efflux of citrate derived from the TCA cycle, which could serve as 
the carbon source for cytosolic lipid synthesis via ATP citrate lyase (39). These 
results potentially provide an indirect mechanism for impaired lipid metabolism in 
FRDA hearts. However, further work is necessary to determine what role, if any, 
impaired lipid homeostasis plays in FRDA. 
There is emerging evidence that Frataxin deficiency may also impair the 
synthesis and maturation of cytosolic and nuclear-localized iron-sulfur cluster 
(ISC)-dependent proteins. Eukaryotic ISCs are generated in the mitochondrial 
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matrix via a complex 190 kDa protein complex composed of Frataxin, NFS1, 
ISD11, and ISCU as described earlier (17). The mitochondria-generated ISCs 
then translocate to the cytosol via the ABCB7 transporter and are incorporated 
into apoproteins via the cooperative functions of Cfd1, Nbp35, IOP1, CIAO1, and 
MMS19 (40). Several proteins involved in DNA replication and repair, telomere 
maintenance, and methionine biosynthesis require an intact ISC and are deficient 
when components of the cytosolic ISC protein assembly machinery are disrupted 
(41). Thus, since extra-mitochondrial ISC proteins also depend on Frataxin for 
their proper assembly, impairments in the aforementioned processes may also 
contribute to disease pathogenesis in Friedreich’s ataxia.  
A multitude of altered cellular processes have been implicated in the 
pathogenesis of FRDA over the seventeen years since the causal gene defect 
was discovered in 1996. The most convincing evidence indicates that lack of 
Frataxin causes respiratory chain defects and consequent ATP deficiency and 
mitochondrial iron-loading. As research progresses, the additional arguments for 
increased oxidative stress, altered lipid homeostasis, and defects in extra-
mitochondrial ISC proteins may become persuasive and influence the rational 
develop of treatments for FRDA.  
 
FRDA Disease Manifestations, Clinical Management, and Emerging 
Treatments 
The cellular consequences of Frataxin deficiency which include ATP 
deficiency, iron accumulation, increased ROS, altered lipid metabolism, and 
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perhaps genomic instability, are all likely to contribute to the clinical 
manifestations of FRDA. FRDA patients typically present with symptoms of ataxic 
gait, fatigue and low energy during their second decade of life, but sometimes 
before 10 years of age. The age of disease onset and length of disease duration 
are inversely correlated with the size of the shorter GAA repeat expansion, with 
longer expansions being associated with earlier age of onset and shorter lifespan 
(42). Consistent with the progressive and degenerative nature of FRDA, the 
majority of patients soon lose ambulatory capability and develop hypertrophic 
cardiomyopathy within 10-15 years of onset. A subset of patients will also 
develop scoliosis, dysarthria, and diabetes (42).  
Consistent with loss of motor coordination, post-mortem analysis of FRDA 
patient nervous tissue has demonstrated smaller dorsal root ganglia, a thinning 
of the spinal cord, and fiber loss in the spinocerebellar and corticospinal tracts. 
The dentate nucleus is also typically atrophied (42). Histochemical observations 
of the dorsal root ganglia demonstrate reduced size of subscapular nerve cells, 
cytoplasmic destruction, and an accumulation of immunoreactive ferritin and 
ferroportin (42, 43). The latter observations are believed to be caused by iron-
loading. The dorsal spinal roots show thinning of myelin sheaths while the 
dentate nucleus exhibits loss of large neurons. 
Upon post-mortem analysis, the gross pathology of the heart generally 
shows hypertrophy, thickening of the left ventricular wall, right ventricular wall 
and interventricular septum (42). As the disease progresses, the left ventricle 
may become dilated (44). FRDA hearts can weigh 2-2.5 times the average for 
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adult men and women (42). Histochemical and ultrastructural observations of the 
FRDA heart show an increase in myocyte size, excessive endomysium, 
scattered iron-reactive inclusions, and proliferation of abnormal mitochondria 
(42). Additionally, the pancreas of FRDA patients who develop diabetes exhibits 
islet loss and shrinkage (42). 
Although FRDA is usually considered a neurodegenerative disorder, the 
most common cause (>60%) of patient mortality is congestive heart failure or 
other heart-related pathology such as arrhythmia (42, 45). Despite the serious 
cardiac manifestations of FRDA, this aspect of the disease is often overlooked 
both in the clinic and in basic research and requires special attention. The most 
common finding among FRDA patients who have cardiac involvement is 
concentric left ventricular hypertrophy. To better understand and diagnose FRDA 
heart disease, a recent study grouped 205 FRDA patients based on the severity 
of their cardiomyopathy which was determined by increasing left ventricular mass 
measured by cardiac MRI. The investigators found that echocardiography 
measurement of end-diastolic thickness of the posterior wall and interventricular 
septum was strongly correlated (P<.049) with myocardial mass, making this 
parameter a reliable and easily accessible measure of left ventricular hypertrophy 
(46). Left ventricular ejection fraction measured by MRI was employed as a 
measurement of cardiomyopathy. In the subset of patients having the greatest 
myocardial mass, there was an observed decrease in the thickness of the 
posterior wall and ventricular septum, which likely indicates a progression toward 
myocardial thinning and dilation which is often accompanied by fibrosis (46). The 
13 
 
authors observed no correlation between cardiac parameters and neurological 
function. In conclusion, the authors recommended performing both cardiac MRI 
and echocardiography of each FRDA patient as early as possible in the disease 
course to establish a baseline from which disease progression and potential 
treatment options can be assessed. 
There currently are no effective or targeted approved treatments for 
mitochondrial disorders with respiratory chain involvement with the exception of 
Coenzyme Q deficiency which can be treated well with dietary Coenzyme Q. The 
general approach to treating mitochondrial disease is the administration of 
antioxidants which are intended to mitigate cellular damage caused by aberrant 
production of reactive oxygen species. Other approaches include identifying 
enzyme deficiencies associated with the primary mitochondrial defect and 
supplementing the patient with the relevant intermediary metabolite. These 
approaches are untargeted and serve to mitigate the downstream consequences 
of the primary deficiency and, in most cases, have little therapeutic efficacy. 
Similarly, approved treatments for Friedreich’s Ataxia are sorely lacking. 
Antioxidant treatment in FRDA has demonstrated moderate biochemical 
improvement but virtually no clinical improvement (47). The observed 
accumulation of mitochondrial iron in FRDA has led to the development of 
membrane permeable iron-chelating drugs such as deferiprone, which have 
demonstrated promise in cellular models of Frataxin deficiency and, more 
recently, in FRDA patients used in combination with the coenzyme Q mimetic 
idebenone (26, 48). Nonetheless, the greatest improvements in neurologic and 
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cardiac parameters in response to treatments are typically experienced by 
younger FRDA patients, while older individuals are less responsive to these 
treatments. This age-dependent response to treatment most likely reflects the 
progressive and worsening nature of FRDA over time and strongly argues for 
early intervention with current or potential future treatment options as well as for 
newborn screening to identify FRDA patients as early as possible (49). 
There are several untargeted interventions for FRDA at various stages in the 
drug development pipeline (Figure 1.2). In addition to deferiprone and idebenone, 
the peroxisome proliferator activated receptor gamma (PPARλ) agonist 
pioglitazone has been advanced as a therapeutic candidate for FRDA after a 
gene expression array study in animal models concluded this pathway was 
dysregulated (50). Despite having advanced through phase II clinical trials, the 
PPARλ agonist approach has elicited some concern among FRDA researchers 
due to findings demonstrating an increased risk of congestive heart failure and 
ischemic events among diabetics using pioglitazone (51). Since cardiomyopathy 
is the most common cause of death in FRDA, pioglitazone could potentially 
exacerbate this condition and promote cardiac pathology. An additional 
therapeutic option being explored for FRDA is the administration of the hormone 
erythropoietin, which was shown to increase Frataxin expression in lymphocytes 
and fibroblasts in vitro (52). However, the results of subsequent clinical trials 
testing the effect of erythropoietin on Frataxin expression have been mixed (53-
55). Future studies are needed to validate the potential use of erythropoietin in 
FRDA treatment. 
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Figure 1.2 A summary of the different approaches to treating FRDA and their 
current stage of clinical development (Courtesy of the Friedreich’s Ataxia 
Research Alliance, FARA, http://www.curefa.org/pipeline.html). 
 
Despite the lack of an effective therapy for FRDA patients, recent progress 
has been made in the development of targeted therapies with the goal of either 
directly increasing Frataxin expression with small-molecule drugs or by replacing 
the deficient protein with exogenous, cell-penetrant Frataxin. Over the past 
several years, Dr. Joel Gottesfeld and colleagues from the Scripps Research 
Institute have approached the treatment of FRDA from an epigenetic standpoint. 
Initially, this group demonstrated that histone deacetylase (HDAC) inhibitors can 
alleviate transcriptional silencing of the FXN locus, which provided rationale for 
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the development of more targeted and specific HDAC inhibitors in order to 
minimize potentially adverse global chromatin remodeling (7). This approach was 
later extended to show HDAC inhibitor-induced upregulation of Frataxin in 
humanized mouse models of FRDA as well partial reversal of an altered gene 
expression phenotype in cultured FRDA patient lymphocytes (32, 56, 57). More 
targeted HDAC inhibitors for increasing Frataxin expression have been 
developed, licensed, and are currently in Phase 1 clinical trials with Repligen 
Corporation (e.g. RG2833). Alternatively, Dr. R. Mark Payne of Indiana University 
has taken the protein replacement therapy approach to treating FRDA. Dr. Payne 
and colleagues have demonstrated that Frataxin can be attached to the cell-
penetrant peptide transactivator of transcription (TAT-Frataxin) which can then 
enter cells, be correctly processed by mitochondrial processing peptidase, and 
can improve biochemical readouts of Frataxin deficiency (58). More importantly, 
TAT-Frataxin treatment can extend the lifespan and improve cardiac parameters 
in the NSE-Cre conditional mouse model of FRDA (59). Unlike the small 
molecule epigenetic approach, exogenous replacement of a mitochondrial 
protein using TAT also has the potential to treat many other mitochondrial 
diseases. The TAT-Frataxin concept is now in the early stages of licensing with 
venture capital and biotech companies for future development as a therapy for 
FRDA.  
The ability to monitor treatment response with biomarkers is extremely 
important in the testing of new drug candidates. Currently, clinical trials for FRDA 
are hampered by the lack of reliable disease biomarkers indicative of an 
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improving or worsening patient condition. This problem also deters drug 
companies from developing treatments for FRDA because they cannot determine 
if their drug is effective. Some studies have suggested measuring serum levels of 
malondialdehyde or oxidized DNA bases as biomarkers (60, 61). More recently, 
a study showed that a serum biomarker traditionally used to measure cardiac 
ischemia, Troponin I, is highly elevated in nearly 50% of FRDA patients, many of 
whom were asymptomatic (62). These findings suggest that measurement of 
serum cardiac troponin may have clinical utility as a biomarker in FRDA. Further 
work on developing disease biomarkers in FRDA is needed in order to more 
accurately monitor disease course and response to potential treatment options. 
  
Mitochondrial Protein Acetylation* 
Over millions of years, eukaryotic organisms evolved fine-tuned metabolic 
mechanisms for orchestrating the conversion of diverse carbon substrates into 
cellular energy. These mechanisms include changes in gene transcription, 
allosteric regulation of metabolic enzymes by fluxing pools of intermediary 
metabolites, and direct regulation by post-translational modifications (PTMs), 
such as phosphorylation. One PTM, lysine acetylation, has been traditionally 
studied in the context of nuclear histone modifications and is well-known to 
influence changes in gene expression (63). However, recent proteomics surveys 
have revealed that lysine acetylation is widespread cellular modification that is 
particularly abundant on mitochondrial proteins, suggesting a new post-
* G. R. Wagner, R. M. Payne, Mitochondrial acetylation and diseases of aging. J Aging Res 2011, 
234875 (2011). 
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translational mechanism for coordinating the metabolism of carbon sources (64, 
65). Accordingly, several studies have demonstrated that reversible lysine 
acetylation can, by targeting key enzymes, modulate the activity of mitochondria-
localized fatty acid β-oxidation, the tricarboxylic acid cycle (TCA), urea cycle, and 
oxidative phosphorylation in a nutrient-responsive manner (66-69). The 
reversible and nutrient-sensitive manner of many of these acetyl-modifications 
has strongly implicated the mitochondrial-localized members of the NAD+-
dependent deacetylases (sirtuins) as regulatory mediators of these fundamental 
metabolic processes (70). Sirtuins are also believed to be part of a genetic 
program influencing the development of age-related conditions such as heart 
disease, neurodegenerative disease, and cancer (71). Although seminal 
discoveries have been made in the basic biology of mitochondrial acetylation, an 
understanding of how acetylation states influence enzyme function and metabolic 
reprogramming during age-associated pathological states remains largely 
unknown. 
This section will examine mammalian acetate metabolism and provide a 
brief history of lysine acetylation as a means to discussing more recent advances 
in mitochondrial acetylation biology and its potential role in the age-related 
conditions of heart failure and cancer, as well as its potential role in human 
longevity. 
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Acetyl-CoA and Metabolism 
Acetate is an ancient energy precursor molecule of metazoan metabolism 
(Figure 1.3). In eukaryotic systems, the principal source of cellular acetate is 
generated by the mitochondrial processes of glucose-derived pyruvate oxidation, 
amino acid catabolism, and the oxidation of even-numbered fatty acyl chains. 
These distinct metabolic pathways are all capable of yielding the activated form 
of cellular acetate, or acetyl-CoA. Thus, acetyl-CoA represents a common 
convergence point for carbohydrate, amino acid, and lipid catabolism. How 
mitochondrial acetyl-CoA is utilized throughout the cell is heavily dependent on 
the cell type and the metabolic state of the organism. However, the primary 
function of acetyl-CoA throughout all cell types is as a carbon donor in the TCA 
cycle. Originally characterized by Hans Krebs and Albert Szent-Györgyi, the TCA 
cycle is a series of substrate oxidation and decarboxylation reactions that serve 
to liberate carbon dioxide and generate electron donors in the form of the 
reduced coenzymes nicotinamide adenine dinucleotide (NADH) and flavin 
adenine dinucleotide (FADH2) (72). The coenzymes NADH and FADH2, in turn, 
serve as high-energy electron donors which are oxidized by the respiratory chain 
complexes to generate the proton-motive electrochemical gradient that is 
ultimately responsible the formation of energy-rich ATP (73). Acetyl-CoA also 
serves as a vital component of anabolic cellular processes. In general, during a 
state of nutrient excess (fed state), a proportion of the excess acetyl-CoA 
generated within the mitochondria is exported into the cytosol in the form of 
citrate, where it is reconverted into acetyl-CoA by ATP-citrate lyase (74). This 
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cytosolic acetyl-CoA can then participate in de novo synthesis of fatty acids and 
sterols that are vitally important for the formation and maintenance of lipid  
 
Figure 1.3 Cartoon schematic summarizing acetyl-CoA metabolism in a 
mammalian cell (39). Please see section entitled “Acetyl-CoA and Metabolism,” 
for a detailed description of figure. Abbreviations: PDH, pyruvate dehydrogenase 
complex; AceCS2, acetyl-CoA synthetase 2; CS, citrate synthase; OA, 
oxaloacetate; AceCS1, acetyl-CoA synthetase 1.  
 
membranes, as well as the synthesis of steroid hormones, triacylglycerols, 
cholesterol, and fat soluble vitamins (75, 76). Lipogenesis primarily occurs in 
hepatocytes and adipocytes whereas cholesterol synthesis primarily occurs in 
hepatocytes. In contrast to the fed state, during a nutrient-depleted state, the liver 
uses TCA cycle intermediates for gluconeogenesis which depletes oxaloacetate 
and limits the entry of acetyl-CoA into the TCA cycle. As the liver continues to 
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oxidize fatty acids for fuel, acetyl-CoA begins to accumulate and is converted into 
the transport forms of acetate known as ketone bodies. Ketone bodies are then 
used as an alternative fuel source in the brain, heart, and skeletal muscle during 
fasting or glucose-scarce conditions (77). Free cytoplasmic and mitochondrial 
acetate can also be converted into acetyl-CoA via the ATP-dependent 
mechanisms of acetyl-CoA synthetase 1 and 2, respectively (78, 79). 
Interestingly, acetyl-CoA synthetase 2 (AceCS2) was recently found to be an 
enzyme critically involved in thermogenesis during fasting conditions (80). 
Through its well-established roles in the generation of cellular energy and as a 
macromolecular building block, acetyl-CoA stands as a critical chemical 
intermediate that is inextricably linked to cellular energy homeostasis. However, 
the fundamental and ancient link between acetyl-CoA, mitochondria, and 
metabolism is underappreciated in the context of acetyl-CoA’s exciting and 
dynamic use as the acetyl group donor for acetyl-lysine post-translational 
modifications. Interestingly, a recent study highlighted this often overlooked 
aspect of acetyl-CoA metabolism by demonstrating that the metabolic enzyme 
ATP-citrate lyase, in addition to its previously mentioned roles in lipid and steroid 
synthesis, also regulates global patterns of histone acetylation and 
corresponding changes in gene expression (81). Therefore, it is nutrient 
availability and metabolism that largely determine the cellular pool of acetyl-CoA 
available for acetyl-lysine protein modifications. 
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Nε- acetylation 
Acetylation occurring on the epsilon-amino group of lysine residues (Nε-
acetylation) was discovered on histone proteins purified from calf thymus over 
forty years ago (82). The ensuing studies of Nε-acetylation focused almost 
exclusively on histone substrates (83-85). It was not until 1996 that Taunton et al. 
purified the first histone deacetylase enzyme (86). This important discovery 
quickly expanded research interest in the field of histone acetylation, and in the 
past 17 years has led to the discovery of numerous enzymes that catalyze the 
addition and removal of acetyl groups, termed histone acetyltransferases (HATs) 
and histone deacetylases (HDACs), respectively. The dynamic and opposing 
functions of HATs and HDACs form the basis for the transcriptional modulation of 
chromatin and the histone code hypothesis (63, 87). Due their role in global 
cellular processes of transcription, HDACs have become attractive 
chemotherapeutic targets. Vorinostat (suberoylanilide hydroxamic acid) is an 
FDA approved HDAC inhibitor that is currently being used for the treatment of 
cutaneous T-cell lymphomas and there are a number of related compounds in 
clinical trials for other neoplastic indications (88).  
Owing to the highly conserved nature of HATs and HDACs across multiple 
eukaryotic species, they are commonly classify according to their homologs in 
yeast (89). There are three primary families of HATs. These include the MYST 
family, the Gcn-5-related N-acetyltransferases (GNATs) and the E1A-associated 
protein of 300 kDa/CREB-binding protein (p300/CBP) family (90). HDACs are 
broadly classified into the Rpd3/Hda1 family of deacetylases, and the silent 
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information regulator-2 (Sir2)-like NAD+-dependent deacetylases/ mono-ADP-
ribosyltransferases, or sirtuins. The Rpd3/Hda1 family are further grouped into 
classes I, II, and IV, while the sirtuins represent class III deacetylases (71, 91). 
Due to the histone-centric nature of the founding studies on acetylation, these 
acetylase and deacetylase enzymes are traditionally referred to as HATs and 
HDACs. However, studies in the past ten years have established that the so-
called HATs and HDACs have multiple non-histone and extra-nuclear targets 
including, among many others, the tumor suppressor p53, the oncogene β-
catenin, and the molecular chaperone HSP90 (92-95). Accordingly, these 
enzymes are now more generally referred to as lysine acetyltransferases (KATs) 
and lysine deacetylases (KDACs). 
Biochemically, the positively charged ε-amino group of lysine residues is 
important for protein stability via hydrogen bonding with nearby amino acid 
residues and can also serve as a base during enzyme catalysis (96) (Figure 1.4). 
The covalent enzymatic addition of an acetyl moiety to the ε-amino group on a 
lysine residue effectively neutralizes its native positive charge, which changes its 
propensity to interact with nearby residues, other proteins, or can alter the activity 
of an enzyme. In its well-established chromatin context, acetylation neutralizes 
positively charged lysine residues on histone tails, thereby reducing its charged 
interactions with other chromatin elements and inducing a “loose” conformation 
that is amenable to transcription factor entry and binding (63). In another context, 
acetylation of lysine 88 on the enzyme ornithine transcarbamylase (OTC) 
changes its affinity for its substrate, carbamoyl phosphate, and negatively  
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 Figure 1.4 The biochemistry of lysine acetylation. Changes in protein function 
and stability known to be associated with lysine acetylation (39). Abbreviations: 
KATs, lysine acetyltransferases; KDACs, lysine deacetylases. 
 
regulates the detoxification of ammonia in the urea cycle (97). Additionally, 
acetylation of lysine 685 on STAT3 promotes its stable dimerization and 
subsequent function as a transcriptional activator (98). The ε-amino groups of 
lysine residues are also the targets of a number of other post-translational 
modifications including methylation, ubiquitination, SUMOylation, and 
NEDDylation. These other modifications may confer their own unique properties 
to proteins and protein functions that could be coordinated with 
acetylation/deacetylation. Ubiquitination of lysine residues, in particular, is known 
cooperate with acetylation to regulate the proteolytic degradation of cellular 
proteins (99). It has also been proposed that acetylation may also act in concert 
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with other distinct post-translational modifications to achieve a broad spectrum of 
functional protein outcomes that has been termed the “protein modification code,” 
analogous to the “histone code” for transcriptional regulation (100). In general, it 
has become clear in recent years that Nε- acetylation is a widespread and 
functionally diverse post-translational modification. 
 
NAD+-dependent deacetylases (Sirtuins) 
In their traditional nuclear context, KATs catalyze the acetyl-CoA 
dependent addition of acetyl groups to disordered histone tails – a mark that 
generally induces a “loose” and transcriptionally active conformation of 
chromatin. In contrast, the traditional functional understanding of KDACs holds 
that they catalyze the H2O-dependent removal of acetyl groups from histone tails 
to induce “tight” and transcriptionally repressed chromatin (87). This well-
established paradigm for transcriptional modulation was broadened with the 
discovery of the mechanistically distinct sirtuin class of deacetylases/mono-ADP 
ribosyltransferases.  
There are seven mammalian sirtuin enzymes. The nuclear-localized family 
members consist of SIRT1, SIRT6, and SIRT7, while SIRT2 is concentrated in 
the cytosol (71). SIRT3, SIRT4, and SIRT5 exhibit mitochondrial localization (71, 
101, 102). Together, the sirtuin family of KDACs are implicated in the regulation 
of a broad scope of biological processes including, but not limited to, 
transcriptional repression, development, apoptosis, DNA repair, cellular stress 
responses, and metabolism (103-107). Sirtuins are unique among the four 
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families of mammalian KDACs in that they catalyze the removal of acetyl groups 
in a fashion that is dependent on the cellular co-enzyme NAD+. The reduced form 
of NAD+, NADH, is generally produced during cellular catabolic processes that 
serve to derive energy from nutrients, whereas the oxidized form, NAD+, 
accumulates within cells during nutrient scarce conditions. Thus, the ratio of the 
reduced form to the oxidized form, or NAD+/NADH, is indicative of the overall 
cellular energy state. Sirtuin deacetylase activity is responsive to this measure of 
cellular energetic balance and require NAD+ as the acceptor of an acetyl group 
from a target acetyl-lysine residue or for protein ADP-ribosylation (108). The 
NAD+-dependent deacetylase reaction yields a deacetylated target protein, 2’-O-
acetyl-ADP-ribose, and nicotinamide, which can then act to inhibit the sirtuin 
reaction mechanism (109). In general, when the cellular NAD+/ NADH ratio is 
elevated during times of exercise, nutrient-restriction or outright fasting, sirtuins 
are presumed to be more actively deacetylating their target proteins, whereas 
during a fed or basal state, NADH predominates and sirtuins are less active. It is 
via their nutrient and stress-sensing capacity to modify transcriptional landscapes 
and modulate enzyme function that sirtuins are believed to mediate the healthful 
benefits of caloric restriction – the only natural means of consistently extending 
lifespan and delaying the onset of age-related pathologies such as cancer in 
mammalian systems (70, 110-113). It is the possibility that the aging process is 
not simply a consequence of time, but rather a program encoded by a set of 
genes, that has excited the research community and has made the sirtuins highly 
attractive therapeutic targets for diseases of aging (114).  
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Mitochondrial sirtuins and Nε-acetylation 
Mitochondria are key organelles for intermediary metabolism as they 
coordinate the conversion of cellular carbon sources into useable energy in the 
form of ATP. The metabolic processes culminating in ATP synthesis are well-
characterized and are regulated by various mechanisms including nutrient 
availability, phosphorylation, allosteric mechanisms, reactive oxygen species, 
and divalent cations such as calcium and magnesium (115-118). In light of the 
established understanding that mitochondria are the primary cellular generators 
of the acetyl-CoA necessary for enzymatic acetylation, it is surprising that Nε-
acetylation within the mitochondria remained virtually unstudied until the last 
decade. The discovery that the sirtuin family members SIRT3, SIRT4, and SIRT5 
localize to the mitochondrial matrix has strongly suggested that acetylation could 
also play an important regulatory role within this organelle (101, 102). An early 
study by Shi, et al. supported this suggestion by demonstrating that SIRT3 
regulates adaptive responses to cold exposure in brown adipose tissue by 
increasing the expression of mitochondrial uncoupling protein-1 (UCP1) and 
thereby increasing mitochondrial respiration (119). Soon after this study was 
published, Schwer, et al. and Hallows, et al., independently confirmed that 
mammalian SIRT3 directly regulates the activity of the mitochondrial protein 
acetyl-CoA synthetase 2 (AceCS2) via NAD+-dependent deacetylation (120, 
121). These findings demonstrated an ancient metabolic regulatory mechanism 
conserved from the prokaryotic bacterium Salmonella enterica to mammals 
(122). Taken together, these early studies not only confirmed reversible Nε-
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acetylation as an important regulatory mark within mitochondria, but also 
implicated the sirtuins as key nutrient-responsive modulators of the functional 
changes acetylation confers upon its target proteins. 
The initial studies of mitochondrial acetylation gave way to global 
proteomics surveys. A 2006 proteomics survey conducted by Kim, et al. revealed 
that over 20% of liver mitochondrial proteins and enzymes are acetylated, and 
that many change acetylation states in response to acute fasting (64). 
Furthermore, enzymes of the major mitochondrial carbon conversion pathways 
such as the TCA cycle and β-oxidation were found to be particularly enriched in 
acetyl-modifications. These findings suggested that reversible acetylation could 
serve as a finely-tuned mechanism for globally regulating the use and conversion 
of carbon energy sources. The authors also demonstrated that a number of the 
mitochondrial enzymes they found to be acetylated have known implications in 
processes of mammalian aging and longevity, such as manganese superoxide 
dismutase (MnSOD) and NADH: ubiquinone oxidoreductase (respiratory complex 
I) (64). Complementing the discovery that global acetylation profiles can change 
in response to nutrient availability, Schwer, et al. showed that global 
mitochondrial acetylation profiles change in multiple organ systems in response 
to long-term caloric restriction (CR) (123). Surprisingly, this study found that the 
vast majority of mitochondrial enzymes exhibited increases in acetylation during 
caloric restriction, which counters the belief that sirtuin-mediated deacetylation 
mediates the beneficial effects of caloric restriction. This finding could suggest 
that mitochondrial sirtuin-mediated deacetylation plays a relatively minor role in 
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the metabolic changes that accompany caloric restriction and that there are more 
complex and undiscovered adaptive mechanisms at play.  
In addition to published acetylation changes during caloric restriction, 
ongoing data from our investigations demonstrate that mitochondrial acetylation 
profiles in the liver, kidney, and brain are different between young and aged 
mice, suggesting that acetylation could mediate age-associated changes in 
metabolism. Similarly, Wang, et al. and Zhao, et al. confirmed the regulatory 
importance of acetyl-modifications in metabolism and in the coordination of 
cellular carbon utilization (65, 124). These proteomics surveys have exposed the 
prevalence of acetylation within mitochondria and reinforced its importance as a 
regulatory modification. Ongoing studies of acetylation changes with age are 
likely to reveal this as an important regulatory mechanism for mitochondrial 
biology.  
Further focused investigations of acetylation within mitochondria have 
concentrated on the role of mitochondrial sirtuins. By generating SIRT3, SIRT4, 
and SIRT5 systemic knockout mouse models, Lombard, et al. demonstrated that 
mice lacking SIRT3 exhibit global hyperacetylation of mitochondrial proteins in 
liver and brown adipose tissue, whereas the acetylation states in mice lacking 
SIRT4 and SIRT5 were relatively unchanged (125). This evidence suggested that 
SIRT3 primarily functions as a deacetylase and potentially targets a wide range 
of mitochondrial proteins, whereas the deacetylase activities of SIRT4 and SIRT5 
are much more restricted. Early characterization of SIRT3 null mice indicated that 
they were phenotypically unremarkable, despite a significant reduction in their 
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liver, heart, and kidney ATP content associated with hyperacetylation and 
reduced activity of mitochondrial respiratory complex I (69). A more thorough 
investigation, however, revealed that SIRT3-/- mice display hepatic lipid 
accumulation during fasting resembling human disorders of fatty acid oxidation 
(66, 126). This study found that SIRT3 directly deacetylates and activates long-
chain acyl-CoA dehydrogenase (LCAD), illustrating a critical mechanism for this 
sirtuin in the metabolic adaptations to fasting and nutrient restriction (66). 
Consistent with SIRT3’s role in oxidative metabolism, Shulga, et al. 
demonstrated that SIRT3 can stimulate oxidative phosphorylation and a shift 
away from glycolysis via inactivation of cyclophilin D, which consequently 
destabilizes the association of hexokinase II with the mitochondria (127). 
Furthermore, mitochondrial isocitrate dehydrogenase (IDH2) is deacetylated and 
activated by SIRT3, thereby regulating a key step in the TCA cycle (67). 
Additional studies have exposed SIRT3 as a regulator of protein translation via 
deacetylation of the mitochondrial ribosome and in the activity of respiratory 
complex II (succinate dehydrogenase) (128, 129). It is now clear that SIRT3 can 
influence the activity of oxidative phosphorylation, fatty acid oxidation, and the 
TCA cycle, positioning this particular sirtuin as a major player in the regulation of 
intermediary metabolism. 
Studies of mitochondrial SIRT4 and SIRT5 are less extensive than those 
for SIRT3. Earlier characterization of mammalian SIRT4 revealed that it chiefly 
functions as an NAD+-dependent mono-ADP-ribosyltransferase that specifically 
ADP-ribosylates and inactivates mitochondrial glutamate dehydrogenase (GDH), 
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thereby regulating amino acid-induced insulin secretion in pancreatic β cells 
(130, 131). Later studies also identified GDH as a target of SIRT3-mediated 
activation via deacetylation, but potential cross-talk with SIRT4-mediated ADP-
ribosylation has not been explored (67, 125). Recently, it was demonstrated in 
vivo that adenoviral-mediated shRNA knockdown of SIRT4 in mouse liver 
increases the expression of genes involved in fatty acid metabolism (132). 
Together, these lines of evidence suggest SIRT4 could play an important role in 
the disruption of lipid homeostasis associated with insulin resistance in type 2 
diabetes. Further characterization of mitochondrial SIRT5 has shown that it 
regulates the first step in the detoxification of ammonia during the urea cycle via 
deacetylation-mediated activation of carbamoyl-phosphate synthetase 1(68). 
Accordingly, SIRT5-/- mice develop hyperammonemia during metabolic states 
demanding greater protein catabolism such as fasting and caloric restriction (68, 
133). Another investigation has suggested SIRT5 can deacetylate cytochrome c, 
a protein involved in mitochondrial respiration and apoptosis (67). The functional 
importance of this relationship, however, has not been determined. SIRT5, on the 
other hand, exhibits weak deacetylase activity and recent in vitro studies suggest 
that SIRT5 functions primarily as a protein de-succinylase and de-malonylase 
(134). Future studies of mitochondrial SIRT4 and 5 are likely to elucidate their full 
regulatory capacity in response to various cellular stresses and stimuli. 
Interestingly, other studies have implicated reversible mitochondrial 
acetylation in mechanisms of cell growth and survival. An early investigation of 
SIRT3’s function in an epithelial cancer cell line indicated that it is required for 
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JNK-regulated cell death via silencing the apoptotic regulator B-cell lymphoma 2 
(bcl-2) (135). In contrast to its role in epithelial cancer, SIRT3 was shown to 
serve a pro-survival function in cardiomyocytes via deacetylating Ku70 and 
promoting the sequestration of the pro-apoptotic protein Bax (104). In addition to 
its apoptotic functions, SIRT3 was more recently demonstrated to be a bona fide 
tumor suppressor by Kim, et al. (136). This study showed SIRT3-/- mouse 
embryonic fibroblasts display reduced antioxidant defenses, which result in a 
lower threshold for tumorigenesis – a finding that confirmed earlier work that 
established SIRT3’s involvement in the transcriptional regulation of antioxidant 
genes (137, 138). Furthermore, the transformation-permissive effect of SIRT3 
ablation can be reversed upon the addition of exogenous MnSOD (136). A 
different study conducted by Yang, et al., established that the levels of 
mitochondrial NAD+ were a critical determinant to cell survival (139). 
Mitochondrial NAD+ levels were shown to be regulated by the rate-limiting 
enzyme in the mammalian NAD+- salvage pathway, nicotinamide 
phosphoribosyltransferase (Nampt). Importantly, the authors demonstrated that 
NAD+-responsive mitochondrial SIRT3 and SIRT4 were required for improved 
cell survival when mitochondrial NAD+-levels rise under conditions of fasting and 
induced genotoxic stress (139). Recently, two independent approaches also 
implicated SIRT3 in the regulation of p53-mediated growth arrest (140, 141). 
Taken together, these studies indicate mitochondrial SIRT3 is a critical mediator 
of cell growth and survival which may hold therapeutic implications in the 
treatment of various cancers.  
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There are also several interesting acetylated mitochondrial proteins 
involved in cellular stress responses and apoptosis on which the effect of 
reversible acetylation has not been studied. These proteins include apoptosis-
inducing factor (AIF) responsible for DNA fragmentation during apoptosis, 
cytochrome c which forms an important component of the apoptosome, and 
voltage-dependent anion channel (VDAC) and adenine nucleotide translocase 
(ANT), both of which are believed to form the mitochondrial permeability 
transition pore during apoptosis (64, 142). MnSOD is also known to be reversibly 
acetylated which may influence the detoxification of mitochondrial reactive 
oxygen species and the overall tendency of a cell to undergo apoptosis (64, 123). 
Furthermore, all of the previously mentioned mitochondrial proteins are reversibly 
acetylated in a nutrient-sensitive manner, suggesting that the apoptotic functions 
of these proteins may be regulated by cellular energy status (64). The study of 
mitochondrial acetylation states in processes of cell death and survival 
represents an entirely open field of study that is rife with intriguing biological 
questions that could provide a new layer of understanding to the mechanisms 
and regulation of apoptosis and cell growth. 
The majority of the studies in the field of mitochondrial acetylation thus far 
have focused on the mitochondrial-localized members of the sirtuin family of 
deacetylases, while the search for the counterbalancing mitochondrial 
acetyltransferase(s) so far has been unsuccessful. Although it is possible that 
certain nuclear-encoded, mitochondrial-targeted proteins acquire acetylation 
marks prior to mitochondrial import, the confirmed acetylation of the 
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mitochondrial-confined ATP synthase subunit 8 protein makes the existence of a 
mitochondrial acetyltransferase(s) possible (64, 142). The marked enrichment of 
acetyl-modifications occurring on enzymes involved in major processes such as 
β-oxidation and redox chemistry (64% and 44%, respectively) over the total pool 
of acetylated mitochondrial proteins (22%), suggests finely-tuned enzymatic 
mechanisms for regulating carbon flux within mitochondria (64). Furthermore, the 
amino acid sequence motifs favoring acetylation within mitochondria differ from 
those of the nucleus and cytosol, suggesting a mitochondrial-specific 
acetyltransferase(s) possessing its own distinct set of substrates (64). Despite 
the evidence for a mitochondrial acetyltransferases(s), it is also important to 
consider the possibility of non-enzymatic acetylation occurring in response to 
changes in the overall mitochondrial acetyl-CoA pool. Indeed, non-enzymatic 
acetylation is known to occur on histone substrates and may account for the 
unexpected increases in mitochondrial acetylation in response to caloric 
restriction (123, 143). The discovery of the mitochondrial acetyltransferases(s) or 
alternative acetylation mechanisms will provide a critical step toward a more 
complete understanding of mitochondrial acetylation biology and its implications 
for disease states. 
 
Mitochondrial acetylation and heart failure 
The recently understood prevalence of acetyl-modifications within the 
mitochondria that can potentially modulate processes of intermediary metabolism 
suggests that altered acetylation could potentially contribute to age-associated 
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disease states in which there are recognized alterations in mitochondrial carbon 
utilization, such as heart failure and cancer.  
The unfortunate progression from increased cardiac workload to 
pathological cardiac hypertrophy and, ultimately, heart failure, occurs when the 
long-term metabolic demands of the body exceed the ability of the pumping heart 
to meet them. Although there are a number of human conditions capable of 
leading to heart failure including renal insufficiency, high blood pressure, and 
cardiac arrhythmias, the leading risk factor is increasing age (144). The role of 
mitochondrial dysfunction in heart failure and the aging process in general is 
well-established. Mitochondrial disorders are often characterized by myopathies 
of the heart and skeletal muscle, as these highly energetic organs are heavily 
dependent on mitochondria-derived energy generation (145). Furthermore, 
cardiomyopathy and heart failure in the general population are often regarded as 
diseases of impaired energy homeostasis associated with a depletion of the 
cardiomyocyte ATP and creatine pools (37, 146). Interestingly, mice lacking the 
predominant mitochondrial NAD+-dependent deacetylase SIRT3 also exhibit 
depleted cardiac ATP levels and further display global hyperacetylation of 
mitochondrial proteins in liver and brown adipose tissue (69, 125). These data 
suggest a role for mitochondrial SIRT3 dysfunction in the pathophysiology of 
heart failure. Several additional studies also stand in support of this notion. As 
discussed earlier, Sundaresan, et al. have shown that SIRT3 promotes 
cardiomyocyte cell survival during genotoxic and oxidative stress (104). This 
group has also revealed that SIRT3 transgenic mice are resistant to agonist-
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induced cardiac hypertrophy via SIRT3-mediated upregulation of antioxidant 
genes (138). Moreover, exogenous administration of NAD+ into the hearts of 
mice was found to abrogate agonist-induced cardiac hypertrophy in a SIRT3-
dependent manner (147). Similarly, transgenic mice harboring cardiac-specific 
overexpression of the NAD+-salvaging enzyme Nampt display reduced infarct 
size following ischemia-reperfusion injury, raising the possibility that the 
cardioprotective effect of increased NAD+ is mediated by the mitochondrial 
sirtuins (148). Pathophysiological cardiac remodeling and heart failure in humans 
are also known to develop in response to alterations in the renin-angiotensin 
system (RAS) (149). One of the RAS signaling proteins, angiotensin II, is often 
used to induce hypertension and cardiac hypertrophy in experimental animals. 
Interestingly, ablation of the angiotensin II type I receptor in mice reduces cardiac 
injury, increases lifespan, and upregulates the expression of SIRT3 and its 
upstream regulator nampt in the kidney (150). Collectively, these studies 
implicate the mitochondrial deacetylase SIRT3 as a major cardioprotective 
enzyme, the modulation of which may hold therapeutic promise in the treatment 
of cardiac disease. 
Mitochondrial oxidative phosphorylation is responsible for generating over 
90% of the energy-rich ATP in the adult human heart (35, 151). Under basal 
conditions, as much as 70% of this ATP is derived from fatty acid β-oxidation and 
the remainder is generated from the oxidation of glucose, lactate, and ketone 
bodies (36). The energetic substrate preferences of the heart can change in 
response to acute stimuli or stressors such as exercise, energy demand, 
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hormonal regulation, ischemia, and substrate availability (36, 152). Thus, the 
healthy heart is a versatile and adaptive consumer of energy substrates. The 
failing heart, however, experiences complex alterations in energy metabolism 
and substrate utilization that are incompletely understood (153). Studies on 
rodent and canine models generally indicate that the failing myocardium suffers 
downregulation of mitochondrial respiratory chain complexes, decreased oxygen 
consumption and ATP generation, decreased flux through the creatine kinase 
system, and impaired fatty acid oxidation (36, 153-156). Many have proposed 
targeting these metabolic rearrangements and altering substrate utilization as a 
therapeutic strategy to treat heart failure (157). Interestingly, numerous 
mitochondrial enzymes of the respiratory chain and involved in the oxidation of 
glucose and fat carry one or more acetylation marks that are reversible in a 
nutrient-sensitive manner. These enzymes include respiratory complexes I, II, 
and V, pyruvate dehydrogenase, several acyl-CoA dehydrogenases, and 
carnitine palmitoyltransferase 1 and 2, among many others (64, 123, 142). It has 
also been demonstrated that the mitochondrial deacetylase SIRT3 can directly 
promote oxidative metabolism via deacetylation-mediated activation of 
respiratory complex 1, LCAD, and cyclophilin D as discussed earlier (66, 69, 
127). The notion that acetylation within the mitochondria can modulate the 
activity of metabolic enzymes implies that there may be altered acetylation states 
within the mitochondria and that they could contribute to the pathophysiology of 
heart failure. More importantly, if this is true, devising strategies that directly 
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target mitochondrial acetylation may provide therapeutic benefit in pathological 
rearrangements of cardiac energy metabolism. 
 
Mitochondrial acetylation and cancer 
In 1924, Otto Warburg made the seminal observation that many cancer 
cells prefer to metabolize glucose into lactate even in the presence of sufficient 
oxygen to support mitochondrial oxidative phosphorylation (158). This 
phenomenon, known as the “Warburg Effect” or aerobic glycolysis, was 
hypothesized by Warburg to be a defect in the mitochondrial metabolism of tumor 
cells (159). In the roughly 70 years following its discovery, little progress was 
made in uncovering the biochemical mechanisms underlying the propensity of 
tumor cells to prefer aerobic glycolysis. The last 15 years of oncology research, 
however, has experienced a renewed interest in understanding the Warburg 
Effect and a number of important discoveries have been made. Notably, it has 
been observed that tumor cell lines almost exclusively express the embryonic 
isoform of the glycolytic enzyme pyruvate kinase (PKM2), which contributes to 
the glycolytic preference and lactate production observed in cancer cells (160, 
161). Recent work conducted by Vander Heiden, et al. has even provided early 
evidence of an alternative carbon utilization pathway in tumors expressing PKM2 
(162). Further work on tumor metabolism has revealed that malignant cells also 
consume large amounts of glutamine in an effort to replenish the TCA cycle 
intermediates necessary for a high rate of macromolecular synthesis that is 
characteristic of rapidly proliferating cells (163). This “glutamine addition” can 
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partially be explained by induction of a transcriptional program that favors 
glutaminolysis via the activation of the proto-oncogene Myc, which can occur in 
many forms of human cancers including neuroblastoma, lymphoma, and small 
cell lung cancer (164-168). Together, these studies and the recent revitalized 
interest in cancer bioenergetics have unveiled some key mechanisms underlying 
the remarkable ability of transformed cells to proliferate. Despite these recent 
advances, there is still much we do not understand about a tumor cell’s aptitude 
for reprogramming metabolism to meet its rapid growth demands and this 
represents an active area of investigation.  
Orchestrating malignant changes in cellular behavior often occurs at the 
level of post-translation regulation. Indeed, many cancers are characterized by 
mutations in, or altered activity of, certain kinases including tumor suppressor 
LKB1, Src, phosphosphoinosital-3-kinase (PI3K), and the mutant BCR-ABL 
fusion kinase, which often occurs in chronic myelogenous leukemia (CML) (169-
172). Additionally, there is an appreciated role for cancer-associated 
transcriptional changes mediated by nuclear KATs and KDACs (88, 173). 
Interestingly, the predominant mitochondrial deacetylase SIRT3 has recently 
been reported to function as a tumor suppressor (136). This work demonstrated 
that SIRT3-/- fibroblasts exogenously transformed with the oncogenes Myc and 
Ras display reduced activity of mitochondrial respiratory complexes I and III 
(136). These results are consistent with earlier work demonstrating direct 
activation of mitochondrial complex I via SIRT3-mediated deacetylation (69). 
Moreover, these findings suggest that there is impaired oxidative phosphorylation 
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and a heavier reliance on glycolytic metabolism in order to satisfy the energetic 
requirements of transformed SIRT3-/- fibroblasts, representing the primary 
hallmarks of the Warburg Effect. Coupling these findings with the knowledge that 
SIRT3 could potentially be regulating numerous mitochondrial proteins suggests 
that SIRT3 dysfunction may represent an important factor contributing to the 
poorly understood metabolic reprogramming that occurs during tumorigenesis 
(125). Consistent with this notion, SIRT3 is known to be downregulated in certain 
breast cancers (136). Furthermore, if SIRT3 can function as a tumor suppressor, 
it is logical to conceive that the putative mitochondrial acetyltransferase(s) 
counterbalancing the tumor-suppressive effects of SIRT3 would be characterized 
as oncogene(s). A multitude of mitochondrial proteins are acetylated in a 
reversible and nutrient- responsive manner. Accordingly, alterations in 
mitochondrial acetylation states, and hence, alterations in carbon substrate 
utilization, may contribute to the unusual preference for aerobic glycolysis and 
glutaminolysis often observed in numerous forms of cancer. 
In addition to understanding the emerging importance of mitochondrial 
acetylation in age-associated diseases, it is also important to briefly discuss 
evidence for its involvement in the aging process in general. Heart failure and 
cancer are two pathophysiological states that display an exponentially increasing 
incidence with advancing age, and a role for the mitochondrial deacetylase 
SIRT3 in these respective conditions has been discussed (144). Complementing 
SIRT3’s emerging role in diseases of aging is the interesting, though 
controversial observation that SIRT3 is the only member of the sirtuin family 
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reportedly linked to longevity in humans. An early study of the human SIRT3 
gene identified a guanine to thymine (G477T) single nucleotide polymorphism 
(SNP) located in exon three to be associated with survivorship in elderly males 
(174). Later, Bellizzi, et al. discovered a variable number of tandem repeat 
(VNTR) polymorphisms possessing enhancer activity at the SIRT3 locus (175). 
The authors of this study further demonstrated that the inactive form of the SIRT3 
enhancer is underrepresented in a population exceeding 90 years of age, and 
thus concluded that the active VNTR enhancer is associated with longevity. 
Additional work has identified the activating elements that bind to this intronic 
VNTR enhancer sequence (176). In contrast to these studies, a meta-analysis of 
SIRT3 SNP data coupled with a larger association study of the SIRT3 
chromosomal region in centenarians indicated no significant genomic variation 
that could be linked to longevity, with the exception of one possible SNP, 
rs939915 (177). Future analysis of genomic variation at the mammalian SIRT3 
locus, transgenic animals, and functional studies of the SIRT3 protein and its 
deacetylation targets will provide much-needed insight into the possible role this 
sirtuin plays in longevity and the aging process. 
 
Summary and objectives 
Although the acetylation of lysine residues has been known as a post-
translational modification for over 40 years, it was not until the last 15 years that 
advances in technology and molecular techniques have enabled the rigorous 
study of this highly interesting regulatory mechanism. We now understand that 
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lysine acetylation rivals phosphorylation, in respect to both the sheer number of 
acetylated proteins in mammalian cells as well as in its regulatory capacity. 
Furthermore, global cellular acetylation states are largely dependent on 
mitochondrial-derived processes of acetyl-CoA formation. Many proteins within 
the mitochondria are now known to be reversibly acetylated and, in some cases, 
acetylation can regulate metabolism and the fate of carbon energy sources. 
Thus, reversible acetylation of mitochondrial proteins represents a new layer of 
protein regulation mediating acute and adaptive changes in mammalian 
metabolism. This new framework for understanding metabolism suggests that 
altered mitochondrial acetylation patterns can contribute to the pathological shifts 
in energy generation that are known to occur during heart failure, the rapid 
proliferation of malignant tumor cells, mitochondrial diseases, and indeed, the 
aging process in general.  
Mitochondrial protein acetylation has not been studied in the context of 
any inherited disease, let alone one with mitochondrial and cardiac 
involvement. Therefore, the objective of the following study was to characterize 
the role of mitochondrial protein acetylation and metabolism in the pathogenesis 
of cardiomyopathy in the inherited mitochondrial disease Friedreich’s Ataxia 
using conditional knockout mouse models. This study sought to 1) Determine if 
acetylation is altered in the Frataxin-deficient heart, 2) If so, understand the 
mechanism of altered acetylation, and 3) Understand alterations in Frataxin-
deficient cardiac mitochondrial metabolism potentially related to protein 
acetylation.  
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CHAPTER II: FRIEDREICH’S ATAXIA REVEALS A MECHANISM FOR 
COORDINATE REGULATION OF OXIDATIVE METABOLISM VIA FEEDBACK 
INHIBITION OF THE SIRT3 DEACETYLASE†  
Abstract  
Friedreich’s Ataxia (FRDA) is the most common inherited human ataxia 
and is caused by a deficiency in the mitochondrial protein Frataxin. Clinically, 
patients suffer progressive spinocerebellar degeneration, diabetes, and a fatal 
cardiomyopathy, associated with mitochondrial respiratory defects. Recent 
findings have shown that lysine acetylation regulates mitochondrial function and 
intermediary metabolism. However, little is known about lysine acetylation in the 
setting of pathological energy stress and mitochondrial dysfunction. We tested 
the hypothesis that the respiratory chain defects in Frataxin deficiency alter 
mitochondrial protein acetylation. Using two conditional mouse models of FRDA, 
we demonstrate marked hyperacetylation of numerous cardiac mitochondrial 
proteins. Importantly, this biochemical phenotype develops concurrently with 
cardiac hypertrophy and is caused by inhibition of the NAD+-dependent SIRT3 
deacetylase. This inhibition is caused by an 85-fold decrease in mitochondrial 
NAD+/NADH and direct carbonyl group modification of SIRT3, and is reversed 
with excess SIRT3 and NAD+ in vitro. We further demonstrate that protein 
hyperacetylation may be a common feature of mitochondrial disorders caused by 
respiratory chain defects, notably, Cytochrome Oxidase I deficiency. These 
findings suggest that SIRT3 inhibition and consequent protein hyperacetylation 
† G. R. Wagner, P. M. Pride, C. M. Babbey, R. M. Payne, Friedreich's ataxia reveals a 
mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 
deacetylase. Hum. Mol. Genet. 21, 2688 (Jun 15, 2012). 
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represents a negative feedback mechanism limiting mitochondrial oxidative 
pathways when respiratory metabolism is compromised, and thus, may 
contribute to the lethal cardiomyopathy in FRDA. 
 
Introduction 
Friedreich’s Ataxia (FRDA) is an autosomal recessive mitochondrial 
disorder caused by a homozygous triplet nucleotide repeat (GAA·TTC) 
expansion in intron 1 of the FXN gene located on chromosome 9q21.11 (2). This 
intronic expansion causes impaired transcription of the FXN gene and, 
consequently, a pathological deficiency of the FXN gene product, Frataxin (5). 
Frataxin is targeted to the mitochondrial matrix, where it is known to act as an 
iron-binding protein and participate in the proper assembly and function of iron-
sulfur cluster (ISC) dependent proteins including complexes I, II, and III of the 
respiratory chain and aconitase of the tricarboxylic acid (TCA) cycle (16, 18, 
178). Thus, Frataxin deficiency severely compromises both cellular respiration 
and overall mitochondrial function leading to energetic stress and ATP deficiency 
(19). Although patients develop multisystem disease including early 
spinocerebellar degeneration, ataxia, and diabetes, the primary cause of death is 
heart failure for nearly 85% of those afflicted (179). Similarly, although the 
phenotypes of the neuron-specific enolase (NSE) and muscle creatine kinase 
(MCK) – Cre conditional mouse models of FRDA differ, both models develop a 
fatal cardiomyopathy and impaired activity of iron-sulfur cluster-dependent 
respiratory complexes consistent with the human disease (15).  
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Recent work has demonstrated that lysine acetylation is a highly conserved and 
abundant post-translational modification within mitochondria that is responsive to 
nutrient availability and may contribute to the physiological adaptations of 
reduced caloric intake (64, 120, 121, 123, 124, 180). Multiple investigations have 
demonstrated a role for reversible mitochondrial enzyme deacetylation and, 
specifically, the NAD+-dependent deacetylase SIRT3, in the regulation of fatty 
acid oxidation, the TCA cycle, electron transport via respiratory complexes I and 
II, and overall oxidative metabolism (66, 69, 129, 181-183). These studies 
suggest that mitochondrial protein acetylation could mediate metabolic changes 
In pathological states characterized by profound energetic stress and impaired 
cellular respiration, such as cardiomyopathies and inherited mitochondrial 
disorders, but this hypothesis remains unexplored (184). Using the above 
mentioned mouse models, we investigated whether acetylation states are altered 
in the setting of FRDA, and if so, sought to determine the mechanism. 
 
Results 
The heart contains the highest density of mitochondria of any organ in the 
mammalian body and heart failure represents the primary cause of death for 
nearly 85% of FRDA patients. Thus, we prepared whole heart lysates from WT, 
NSE, and MCK conditional mouse models of FRDA and performed Western blot 
analysis to assay protein acetyl-lysine modifications. Figures 2.1A & B show that 
heart lysates from both the NSE and MCK mouse models of FRDA exhibited  
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 Figure 2.1 Frataxin-deficient hearts exhibit marked protein hyperacetylation 
(185). (A) Western blot (WB) probing for internal acetyl-lysine residues using total 
heart homogenates derived from 24 day-old wild-type (WT, n=2, lanes 1 and 2) 
and 24 day-old NSE-Cre mouse models of FRDA (n=2, lanes 3 and 4). Below 
this, the corresponding SDS-PAGE gel stained with Coomassie Blue and a 
Western blot probing for Frataxin. (B) Similar to (A) only using total heart 
homogenates prepared from 9 week-old WT (n=2, lanes 1 and 2) and 9 and 11 
week-old MCK-Cre mouse models of FRDA (lanes 3 and 4, respectively). Below, 
the corresponding gel stained with Coomassie Blue and a Western blot probing 
for Frataxin. See also Figure S1. kDa: molecular weight in kilodaltons. (C) The 
average relative integrated densitometry values from the acetyl-lysine Western 
blot in (A) are shown (mean± SD; * P< .05). (D) The average relative integrated 
densitometry values from the acetyl-lysine Western blot in (B) are shown (mean± 
SD; * P< .05). 
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marked increases in acetyl-lysine modifications as compared to age-matched 
control hearts, and these are significant (Figure 2.1C & D). The differences were 
most dramatic in proteins with an estimated molecular weight between 
approximately 30 and 75 kDa. In contrast to heart tissue, whole brain lysates 
from the NSE models and skeletal muscle lysates from the MCK models showed 
no change in acetylation state when compared to WT control lysates (Figure 2.2). 
 
 
Figure 2.2 NSE brain and MCK skeletal muscle do not show altered acetylation. 
NSE mouse model whole brain lysate and MCK mouse model whole skeletal 
muscle lysate exhibit no change in acetylation state when compared to age-
matched WT control tissues. 
 
Cardiac cellular sub-fractionation of heart samples to determine the sub-
cellular distribution of hyperacetylated proteins. Analysis of the purity of these 
48 
 
mitochondrial preparations showed that nuclear and cytosolic proteins were 
excluded and they were highly enriched for markers of both the outer and inner 
mitochondrial membranes (Figure 2.3A). Using day 24 wild-type (WT, n=2) 
control and NSE-Cre Frataxin-deficient cardiac mitochondrial preparations (n=2), 
we performed Western blot analysis for acetyl-lysine modifications. Control 
cardiac mitochondria exhibited several acetylated proteins detectable by Western 
blot which is consistent with prior findings (123). However, Frataxin-deficient 
cardiac mitochondria displayed marked hyperacetylation of numerous proteins 
(Figure 2.3B and Figure 2.4). This was accompanied by a characteristic 
downregulation of respiratory complex I and II (succinate dehydrogenase) that 
was present as early as 7 days post-natal (Figure 2.5). Levels of the dominant 
mitochondria-localized NAD+ -dependent deacetylase SIRT3 displayed a mild, 
though insignificant, increase in Frataxin-deficient mitochondrial preparations 
(Figure 2.3B and C), which is consistent with prior work demonstrating induction 
of SIRT3 in cultured cardiomyocytes subjected to various forms of stress (104). 
These results indicated that the hyperacetylation observed at the level of whole 
cardiac lysate is predominantly localized to mitochondria. 
Because the NSE-Cre mouse models of FRDA only begin to develop 
cardiac hypertrophy in their second week of life (15), we next sought to examine 
the developmental profile of mitochondrial protein acetylation. We prepared 
cardiac mitochondria for Western analysis from WT control and NSE-Cre mice at 
post-natal days 7, 17, and 24. At post-natal day 7, NSE-Cre cardiac 
mitochondrial proteins exhibit only a mildly increased acetylation state as 
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compared to their wild-type counterparts (Figure 2.3D and 2.5). However, at 
post-natal day 17, NSE-Cre cardiac mitochondria display increased acetylation of 
cardiac mitochondrial proteins as compared to their WT counterparts and this 
difference becomes more dramatic by post-natal day 24. Importantly, the 
progressive increase in cardiac mitochondrial protein acetylation over this time 
frame corresponded with the development of cardiac hypertrophy in the NSE-Cre 
models (Figure 2.3E). 
Prior work had demonstrated that genetic ablation of the deacetylase 
SIRT3, but not SIRT4 or SIRT5, caused hyperacetylation of mitochondrial 
proteins in liver and brown adipose tissue (186). These findings immediately 
suggested that hyperacetylation in Frataxin deficiency could be caused by 
impairment or inhibition of SIRT3. Respiratory chain dysfunction is known to alter 
the cellular and mitochondrial redox state (NAD+/NADH) via impaired oxidation 
and consequent accumulation of NADH generated by the TCA cycle (187-189). 
Importantly, sirtuin activity is responsive to redox state (190), although this 
finding is somewhat controversial (191). Thus, we determined the redox state of 
WT and Frataxin-deficient cardiac mitochondria preparations. WT heart 
mitochondria displayed robust NAD+ levels and over 100-fold less NADH by 
comparison, which is consistent with highly oxidative cardiac catabolism and a 
continuous demand for carbon fuels (Figure 2.6A). Frataxin-deficient 
mitochondria displayed a mild, though insignificant, increase in NAD+ levels when 
compared to WT. In striking contrast, Frataxin-deficient mitochondrial NADH 
50 
 
levels were, on average, over 95-fold greater than in WT mitochondria (P<.005) 
resulting in a corresponding NAD+/NADH ratio that was 85-fold less than in WT  
 
Figure 2.3 Hyperacetylation in Frataxin-deficient hearts is localized to 
mitochondria and develops progressively with cardiac hypertrophy (185). (A) 
Western blot (WB) demonstrating the purity of the cardiac mitochondrial 
preparations. Histone H3 was used as a nuclear marker, GAPDH as a 
cytoplasmic marker, VDAC as a mitochondrial outer membrane marker, and 
Complex II as a mitochondrial inner membrane marker. (B) Hyperacetylation is 
localized to cardiac mitochondria. Western blot probing for internal acetyl-lysine 
residues using 25 µg of isolated mitochondrial protein derived from 2-3 pooled 
hearts from 24 day-old wild-type (WT, n=2, Lanes 1 and 2) hearts and 24 day-old 
NSE Frataxin KO hearts (n=2, Lanes 3 and 4). Below, a series of Western blots 
probing for the respiratory Complex I subunit NDUFA9, the Complex II 30 
kilodalton iron-sulfur subunit, the Complex III Rieske protein, and the NAD+-
dependent deacetylase SIRT3. The mitochondrial outer membrane protein 
voltage-dependent anion channel (VDAC) was used as a loading control. See 
also Figure 3.4. kDa: molecular weight in kilodaltons. (C) The calculated 
densitometry for SIRT3 relative to the loading control VDAC shown in Figure 2B 
(mean ± SD; N.S.: not significant). (D) Hyperacetylation develops progressively. 
Western blot probing for internal acetyl-lysine residues in 25ug of mitochondrial 
protein preparations isolated from 2-3 WT or NSE-Cre Frataxin knockout hearts 
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at day 7, day 17, and day 24 in their post-natal development. Below, a Western 
blot probing for Frataxin and VDAC was used as a loading control. Note: Due to 
very small amounts of heart material and inefficient mitochondrial isolation at 
post-natal Day 7, mitochondrial protein from day 7 WT and NSE animals was 
overloaded by 18.2% and 62%, respectively, with respect to the other samples to 
achieve normalization of mitochondrial protein. See also Figure S2. kDa; 
molecular weight in kilodaltons. (E) Cardiac hypertrophy develops concurrently 
with protein hyperacetylation. A graph assessing the post-natal development of 
cardiac hypertrophy in the NSE KO mice as measured by heart weight divided by 
body weight (mean ±SD; n= 3 measurements at each time point; *P<.05). 
 
animals (Figure 2.6A inset). The observed accumulation of NADH and 
consequent shift in mitochondrial redox state is consistent with the impairments 
of mitochondrial respiration found in both human FRDA patients, and the NSE 
and MCK animal models (15, 18).  
An increased sensitivity to oxidative stress is believed to contribute to the 
pathogenesis of FRDA (192). A proteomics investigation of the MCK mouse 
heart revealed upregulation of the antioxidant enzymes glutathione S-transferase 
and DJ-1 (193). Furthermore, FRDA patients were shown to have increases in 
plasma levels of malondialdehyde, a product of lipid peroxidation (60). A recent 
report demonstrated that SIRT3 can be directly modified and allosterically 
inhibited by sub-physiological levels of 4-hydroxy-2-nonenal (4-HNE), an 
endogenous product of lipid peroxidation (194). Therefore, we investigated if 
SIRT3 is differentially modified by 4-HNE in Frataxin-deficient cardiac 
mitochondria. We pulled down all reactive aldehyde containing mitochondrial 
proteins following their derivatization to biotin hydrazide, and then performed 
Western blot analysis for SIRT3. SIRT3 in WT heart mitochondria exhibited a 
small amount of 4-HNE modification. In contrast, SIRT3 in Frataxin-deficient 
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mitochondria exhibited a marked increase in 4-HNE modification, (Figure 2.6B) 
suggesting that SIRT3 may be directly inhibited via carbonyl group adduction in 
the setting of Frataxin deficiency. We next analyzed the acetylation states of 
 
Figure 2.4 Protein hyperacetylation in Frataxin-deficient hearts is localized to 
mitochondria (185). Western blot on 20 µg of total heart homogenate, 
cytoplasmic fraction, and mitochondrial fraction probing for internal acetyl-lysine 
residues. Below, Western blots probing for the mitochondrial marker complex II 
iron-sulfur subunit and the cytoplasmic marker GAPDH.  
 
known targets of SIRT3-mediated deacetylation. The Complex I subunit NDUFA9 
was previously found to be a specific target of SIRT3-mediated deacetylation 
(69). To test the hypothesis that SIRT3 is inhibited in Frataxin-deficient hearts, 
we immunoprecipitated mitochondrial acetyl-lysine proteins followed by Western 
blot analysis for NDUFA9. Consistent with previous findings, we observed a 
minimal amount of NDUFA9 acetyl-lysine signal in the WT mitochondrial 
immunoprecipitate. However, the Frataxin-deficient mitochondrial 
immunoprecipitate displayed a greater acetylated NDUFA9 signal despite 
downregulation of NDUFA9 as seen in the input (Figure 2.6C). We additionally 
analyzed the acetylation state of a second specific target of SIRT3-mediated 
deacetylation, acetyl-CoA synthetase 2 (AceCS2) (120, 121). Similarly, this 
analysis revealed a greater amount of acetylated AceCS2 in the Frataxin-
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deficient condition as compared to the WT (Figure 2.6D). The increased 
acetylation states of two known targets of SIRT3-mediated deacetylation 
indirectly demonstrated that SIRT3 is inhibited in Frataxin-deficient cardiac 
mitochondria. Importantly, increases in the acetylation states of NDUFA9 and 
 
 
Figure 2.5 Frataxin-deficient cardiac mitochondrial proteins display increases in 
acetylation as early as post-natal day 7. They also exhibit downregulation of the 
respiratory complex II iron-sulfur subunit (185). VDAC was used as a loading 
control. 
 
AceCS2 are linked to a decrease in the activity of respiratory complex I and the 
synthesis of activated acetate, respectively (69, 120).  
Prior studies have demonstrated that SIRT3 exhibits acetyl-lysine target 
specificity and does not deacetylate all acetyl-lysines present on a target protein 
(66, 195). Based on these findings, we reasoned that if hyperacetylation of 
Frataxin-/- mitochondrial protein lysine residues were caused by an inhibition of 
endogenous SIRT3, then incubating with excess SIRT3 and NAD+ in vitro would 
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restore SIRT3 activity resulting in deacetylation of its specific acetyl-lysine 
targets. Accordingly, we incubated solubilized WT and Frataxin-deficient cardiac 
mitochondrial proteins with glutathione S-transferase tagged, processed human 
recombinant SIRT3 (GST-hSIRT3) in the presence or absence of NAD+ to assay 
for changes in acetylation states. Incubating solubilized WT or Frataxin-/- cardiac 
mitochondrial homogenates with NAD+ alone caused no change in acetylation 
signal. In contrast, incubating Frataxin-deficient mitochondrial protein with 3 µg of 
GST-hSIRT3 and NAD+ resulted in a marked reduction of acetyl-lysine signal 
from nearly every protein band, while completely eliminating the acetyl-lysine 
signal of multiple bands (Figure 2.6E). Furthermore, the observed reduction in 
acetylation signal was abolished upon withdrawal of NAD+ from the incubation 
buffer, demonstrating that the hyperacetylated protein lysine residues in Frataxin-
deficient cardiac mitochondria are, indeed, specifically sensitive to NAD+-
dependent SIRT3-mediated deacetylation and that the observed hyperacetylation 
is not caused by a general increase in non-specific lysine acetylation. Taken 
together, these data strongly suggest that hyperacetylation in Frataxin-deficient 
mitochondria is due to both redox-state and lipid-peroxidation-mediated inhibition 
of endogenous SIRT3. 
We obtained cardiac mitochondria from SIRT3 KO animals on a C57BL/J6 
genetic background to compare acetylation profiles with our Frataxin-deficient 
cardiac mitochondria. In spite of the differences between the two animal models 
including genetic background, age, and one a model of disease and the other a 
simple gene ablation, comparing the acetylation state of Frataxin-deficient 
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cardiac mitochondria to SIRT3-deficient cardiac mitochondria yielded many 
similarities. Both models exhibited hyperacetylation of mitochondrial proteins and 
many hyperacetylated protein bands appeared at identical molecular weights 
(Figure 2.7). The Frataxin-deficient cardiac mitochondria displayed an overall 
 
Figure 2.6 Hyperacetylation in Frataxin-deficient hearts may be caused by 
impaired SIRT3 activity (185). (A) Determination of nicotinamide adenine 
dinucleotide (NAD+) and reduced NAD+ (NADH) levels in WT and Frataxin-
deficient cardiac mitochondrial preparations. Individual measurements were 
performed on a pooled sample of at least 300 µg of fresh cardiac mitochondria 
derived from 2-3 hearts and normalized to total mitochondrial protein input (n=3-5 
biological replicates per condition, mean± SD; ** P<.005). Figure inset: the ratio 
of NAD+ to NADH for WT and NSE-KO heart mitochondria. (B) SIRT3 is 
differentially modified by a carbonyl group in Frataxin-deficient mitochondria. This 
modification was previously shown to allosterically inhibit SIRT3 activity (194). 
The shown figure is representative of two independent experiments. (C) Targets 
of SIRT3-mediated deacetylation are hyperacetylated in Frataxin-deficient hearts. 
Immunoprecipitation of 500ug WT and NSE-Cre cardiac mitochondrial proteins 
with an acetyl-lysine antibody and subsequent Western blot probing for a known 
target of SIRT3-mediated deacetylation, the respiratory complex I subunit 
NDUFA9. Below, Western blots of 2 percent of the total mitochondrial lysate 
input used for the immunoprecipitations showing NDUFA9, SIRT3, Frataxin, and 
the acetylation states of both samples. Cardiac mitochondrial preparations were 
derived from 2-3 pooled hearts per condition. The figure shown is representative 
of three independent experiments. (D) Similar to (C), only examining acetyl-CoA 
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synthetase 2 (AceCS2) as a target of SIRT3-mediated deacetylation. (E) 
Recombinant SIRT3 in the presence of 10mM NAD+ reverses mitochondrial 
protein hyperacetylation in Frataxin-deficient hearts. Below are Western blots 
showing recombinant SIRT3, endogenous SIRT3, and VDAC which was used as 
a loading control. kDa; molecular weight in kilodaltons. 
 
Figure 2.7 Comparing the cardiac mitochondrial protein acetylation profiles 
between SIRT3 KO and Frataxin KO animals. The arrows indicate a protein band 
which is hyperacetylated in both the SIRT3 KO and Frataxin KO conditions. 
Below, a Western Blot probing for SIRT3 and VDAC as a mitochondrial loading 
control. 
 
increase in acetylation intensity as compared to the SIRT3-deficient cardiac 
mitochondria. This could suggest that a portion of the acetylation observed in 
Frataxin-deficient mitochondria occurs independently of SIRT3 inhibition. 
Alternatively, this finding could reflect differences in the abundance of acetylated 
proteins between substantially different animal models. Nonetheless, these 
results further support the findings that hyperacetylation of mitochondrial proteins 
in the Frataxin-deficient heart is, in part, caused by a loss of SIRT3 deacetylase 
activity.  
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Friedreich’s Ataxia is a mitochondrial disorder that has a distinctive cause 
and unique pathogenesis. However, the observed accumulation of NADH in 
Frataxin-deficient mitochondria and consequent drop in NAD+/NADH ratio is 
often a common biochemical feature of respiratory chain disorders, regardless of 
mutational origin (38, 189, 196). Taking this common feature into consideration 
with the findings that SIRT3 deacetylase activity is NAD+-dependent and likely to 
be responsive to this change in mitochondrial NAD+/NADH balance, we 
hypothesized that other mitochondrial disorders caused by respiratory chain 
defects would display alterations in cardiac acetylation profiles. To test this, we 
obtained whole cardiac lysates from the cytochrome oxidase I (COI) mouse 
model, which harbors a mitochondrial DNA mutation causing a defect of 
respiratory complex IV, and the adenine nucleotide translocase knockout (ANT1-/-
) mouse model, which models a non-respiratory chain defect with a deficiency of 
ATP translocation (197, 198). These mice model the human mitochondrial 
disorders autosomal dominant progressive external ophthalmoplegia (adPEO), 
and Leber’s Hereditary Optic Neuropathy (LHON), respectively, and both models 
develop cardiomyopathy (199, 200).  
Analyzing cardiac acetylation via Western blot revealed mild to moderate 
increases in acetylation in 12 month old COI hearts as compared to 13 month-old 
control hearts (Figure 2.8A). Interestingly, 20 month old ANT1-/- hearts exhibited 
a small decrease in acetyl-lysine profiles when compared to 18 month old control 
hearts (Figure 2.8B). Taken together with our data from the Frataxin-deficient 
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mice, these results suggest that increases in protein acetylation may be a 
common feature of respiratory chain malfunction in the mammalian heart. 
 
Figure 2.8 Respiratory chain defects may cause protein hyperacetylation (185). 
(A) Western blot probing for internal acetyl-lysine residues using 25 µg of whole 
heart lysate derived from a 13 month-old wild-type (WT) animal and a 12 month-
old animal harboring a missense mutation in the mitochondrial genome-encoded 
protein subunit of the respiratory chain enzyme cytochrome c oxidase (COI). 
Below, the same membrane used for Western blotting above stained with the 
non-specific protein marker Ponceau S. (B) Western blot probing for internal 
acetyl-lysine residues using 25 µg of whole heart lysate prepared from a 18 
month-old WT animal and a 20 month-old animal lacking the non-respiratory 
chain mitochondrial inner membrane protein adenine nucleotide translocase 1 
(ANT1-/-). Below, the same membrane used for Western blotting above stained 
with Ponceau S. (C) The calculated integrated densitometry values for acetyl-
lysine signal relative to Ponceau S signal from Figure 4A. (D) Similar to C, only 
calculated from Figure 4B. kDa; molecular weight in kilodaltons. 
 
Discussion 
In this study, it was demonstrated that the respiratory chain defects 
accompanying Frataxin deficiency cause progressive hyperacetylation of cardiac 
mitochondrial proteins due to the inhibition of a major positive regulator of 
oxidative metabolism, the SIRT3 deacetylase (183, 201). These findings present 
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a novel disease phenotype and reveal a negative feedback mechanism that may 
serve to coordinately suppress mitochondrial oxidative pathways, and that may 
be hyperactive in the setting of respiratory chain malfunction.  
Defects in cellular respiration can be inherited as mitochondrial disease, or 
acquired over a lifetime via somatic mutations, and are linked to many conditions 
including neurodegenerative disease, diabetes, heart failure, cancer and indeed, 
the aging process in general (196). The involvement of cellular respiration in 
numerous common human pathologies emphasizes the need for greater 
understanding of the pathophysiological processes that occur in response to 
respiratory chain compromise. SIRT3-mediated deacetylation has recently 
emerged as a major mechanism regulating the activity of mitochondrial oxidative 
and intermediary metabolism. SIRT3 is also uniquely poised to respond to the 
flux of mitochondrial NAD+ and NADH, which is determined, in large part, by the 
capacity of the respiratory chain to oxidize NADH. This capacity is severely 
decreased in FRDA, as well as in other mitochondrial defects such as 
cytochrome c oxidase (complex IV) deficiency (187), causing an accumulation of 
NADH and, consequently, a redox state of perceived nutrient excess. In this 
setting, it is logical to predict that mitochondria would have a mechanism to 
restrain oxidative metabolism and the further generation of NADH, as well as 
spare the cell from damaging ROS that would be produced by forcing electrons 
through a dysfunctional respiratory chain. Indeed, it has been known for several 
decades that a decrease in NAD+/NADH redox balance has a largely inhibitory 
effect on many enzymes of intermediary mitochondrial metabolism (202). Based 
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on these observations and predictions, our data suggests that this mechanism 
involves inhibition of the NAD+-dependent SIRT3 deacetylase mediated through 
a dramatic decrease in mitochondrial redox-state, as measured by the 
NAD+/NADH ratio, and direct modification by lipid peroxidation. 
Recent studies have shown that SIRT3-mediated deacetylation activates 
the respiratory chain via Complexes I and II, fatty acid oxidation via LCAD, the 
TCA cycle via isocitrate dehydrogenase, and the production of acetyl-CoA via 
AceCS2, among others (66, 69, 120, 129). Additionally, SIRT3 deficient 
fibroblasts show a decrease of carbon intermediates in the TCA cycle (203). 
Together, these studies indicate a key role for SIRT3 in the maintenance of 
oxidative metabolism (183) and may be especially important in the heart, which 
derives as much as 90% of its ATP from oxidative phosphorylation (35). Indeed, 
SIRT3 deficient mice exhibit reduced cardiac ATP levels, are hypersensitive to 
cardiac stress, and develop an early onset cardiac hypertrophy (69, 138, 204). 
These findings suggest that SIRT3 inhibition, in addition to impaired ISC 
biosynthesis, may contribute to FRDA cardiomyopathy by further limiting key 
components of oxidative and intermediary metabolism, such as the respiratory 
chain, the TCA cycle, and the β-oxidation of fatty acids. In addition to its 
metabolic functions, SIRT3 is known to directly activate antioxidant defense 
mechanisms via deacetylation of mitochondrial MnSOD and isocitrate 
dehydrogenase of the glutathione system (182, 205, 206). These important 
findings suggest that inhibition of SIRT3 in FRDA could underlie the increased 
sensitivity to oxidative stress (192). Thus, it is logical to predict that Frataxin 
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deficiency promotes a vicious cycle whereby improper assembly of ISC-
dependent respiratory complexes and their consequently reduced activity causes 
SIRT3 inhibition, leading to the accumulation of protein lysine acetylation which 
further inhibits the activity of the respiratory chain and oxidative metabolism 
(Figure 2.9). This model would be consistent with the progressive increase in 
mitochondrial protein acetylation we observe during the post-natal development 
of the NSE-Cre Frataxin-/- mice (Figure 2.3D). Interestingly, a recent report noted 
that Frataxin-deficient yeast show decreased acetylation of mitochondrial 
proteins (207), which may reflect the yeast preference for glucose as a carbon 
source instead of fatty acids utilized by heart mitochondria, or that no sirtuins are 
known to function within yeast mitochondria. The extent to which SIRT3 inhibition 
and mitochondrial protein hyperacetylation influence these diverse processes 
and the pathogenesis of FRDA cardiomyopathy is likely to be very important and 
remains to be explored. 
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 Figure 2.9 Cartoon schematic summarizing the proposed mechanism of SIRT3 
inhibition in Frataxin-deficient cardiac mitochondria (185). Impaired ISC 
biosynthesis in Frataxin-/- mitochondria results in defects of respiratory 
complexes I, II, and III, which cause impaired oxidation and accumulation of 
NADH generated by the TCA cycle. The resulting dramatic decrease in the 
mitochondrial NAD+/NADH ratio (redox state) creates a reducing environment 
mimicking nutrient excess. In addition, an increased sensitivity to oxidative stress 
consequently promotes lipid peroxidation and the formation of 4-HNE protein 
carbonyl adducts. The dramatic decrease in mitochondrial redox state and 
increase in 4-HNE modified SIRT3 work in concert to inhibit SIRT3 activity, 
causing protein hyperacetylation and most likely reduced activity of SIRT3 target 
proteins which have been shown to play key roles in the maintenance of 
oxidative and intermediary metabolism. OMM: outer mitochondrial membrane, 
IMS: intermembrane space, IMM: inner mitochondrial membrane, ROS: reactive 
oxygen species, 4-HNE: 4-hydroxy-2-nonenal, NDUFA9: NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 9, AceCS2: acetyl-CoA synthetase 2. 
 
 
 
 
63 
 
Materials & Methods 
Animal use statement. The use of laboratory mice in this study was approved 
by the Indiana University School of Medicine’s Institutional Animal Care and Use 
Committee (IACUC) and Laboratory Animal Resource Center (LARC). All 
conducted experiments conform to the American Veterinary Medical 
Association’s Panel on Euthanasia. 
Frataxin conditional knockout mouse breeding and genotyping. Mice 
homozygous for a floxed exon 4 of the Frda gene (FrdaL3/L3) were crossed with 
mice heterozygous for a deletion of Frda exon 4 (Frda+/Δ) carrying a tissue-
specific Cre transgene driven by the neuron-specific enolase (NSE), or muscle 
creatine kinase (MCK), promoters to generate a mouse with Frda exon 4 deletion 
restricted primarily to the heart and brain or heart and skeletal muscle, 
respectively (15). The primers used to detect the presence of exon 4 for 
genotyping were 5’-CTGTTTACCATGGCTGAGATCTC-3’ and 5’-
CCAAGGATATAACAGACACCATT-3’ which generates a 500 bp product. The 
primers used to detect the presence of the Cre transgene were 5’-
CCGGTCGATGCAACGAGTGAT-3’ and 5’-CAAAGAGTCAT CCTTAGCGCC-3’, 
which generate a 790 bp band. Mice that are genotyped as FrdaL3/Δ, Cre+ 
represent the conditional knockout animals. 
Mouse tissue preparation. For the isolation of whole heart, brain, skeletal 
muscle, or liver homogenate, animals were sacrificed by CO2 asphyxiation and 
the tissue was immediately excised, washed and minced in cold phosphate-
buffered saline. The tissue was then placed in 1-2 ml of ice-cold complete RIPA 
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buffer containing an EDTA-free protease inhibitor cocktail (Roche product 
#05056489001), and 10 mM nicotinamide (NAM), 200 nM Trichostatin A, and 5 
mM sodium butyrate as deacetylase inhibitors. The tissues were then 
homogenized with at least 10 passes of a motor-driven Potter-Elvehjem 
homogenizer at high speed. The whole tissue lysates were then transferred to 
1.5 ml tubes and spun at 17,000 x g for 10 min at 4°C in a desktop centrifuge to 
pellet membranes and tissue debris. The supernatant was saved and 
immediately frozen on dry-ice for later analysis. Frozen, RIPA buffer solubilized 
ANT1 -/- and COI missense mutation cardiac lysates were a generous gift of Dr. 
Douglas C. Wallace. 
Isolation of Cardiac Mitochondria. Wild-type or Frataxin conditional KO mice 
were sacrificed by CO2 asphyxiation and their hearts were immediately removed 
and submerged in ice-cold mitochondrial isolation buffer (MIB) containing 220mM 
mannitol, 70 mM sucrose, 30 mM Tris-Cl (pH 7.4), 0.5 mM EGTA, and 0.1% 
BSA. Heart tissue was minced and washed in MIB to eliminate blood and serum 
contaminants, then quickly weighed. Minced heart tissue from 2-3 animals was 
submerged 3 ml/g MIB containing an EDTA-free protease inhibitor cocktail 
(Roche) and 10 mM nicotinamide (NAM), 200 nM Trichostatin A, and 5 mM 
sodium butyrate as deacetylase inhibitors. Heart tissue was homogenized with 
four passes of a motor-driven Potter-Elvehjem homogenizer with a Teflon pestle 
at medium speed on ice. An additional 7 ml/g MIB was added to the heart 
homogenate, which was then transferred to a pre-chilled 50 ml conical tube. A 
crude mitochondrial pellet was obtained via a standard differential centrifugation 
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method. Briefly, nuclei and the heavy cell fraction are removed via centrifugation 
for 15 minutes at 1000 x g at 4°C. The resulting post-nuclear supernatant was 
subjected to centrifugation for 15 min at 10,000 x g to pellet mitochondria. The 
supernatant was removed as the cytosolic fraction and sedimented mitochondria 
were gently resuspended in 1 ml ice-cold MIB containing deacetylase inhibitors 
and then diluted with MIB to a total volume of 10ml and centrifuged again for 15 
min at 10,000 x g. The supernatant was then removed and sedimented 
mitochondria are gently washed in 0.5 M KCl to remove endoplasmic reticulum 
and lysosome contaminants as described previously (208). When the 
downstream application was Western blotting, the sedimented mitochondria were 
solubilized in complete RIPA buffer containing protease and deacetylase 
inhibitors (see Mouse tissue preparation) and frozen until later analysis. For 
immunoprecipitations, the pelleted mitochondria were resuspended in ice-cold 
buffer containing 50 mM Tris-Cl (pH 7.4), 150 mM NaCl, and an EDTA-free 
protease inhibitor tablet and immediately frozen at -80°C. For NAD+ and NADH 
measurements, sedimented mitochondria were immediately resuspended in 180 
µl of ice-cold 1mM Tris-Cl pH 7.4, 150 mM NaCl and extracted appropriately (see 
Mitochondrial NAD+ and NADH measurements). 
Antibodies and Western Blotting. Antibodies used in this study include anti-
acetyl-lysine and acetyl-lysine antibody-conjugated agarose beads 
(Immunechem), anti-acetyl-lysine (Cell Signaling), anti-complex II 30 kDa 
subunit, anti-NDUFA9 and anti-aconitase (Mitosciences), anti-SIRT3 (gift of 
E.Verdin, Gladstone Institute, UCSF (66)), anti-Frataxin (gift of G. Isaya, Mayo 
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Clinic), anti-SIRT3 D22A3, anti-VDAC D73D12, and anti-histone H3 (Cell 
Signaling), anti-Gapdh and anti-tubulin (Sigma), and anti-AceCS2 
(ACSS1)(Abcam). Following transfer of the SDS-PAGE gel proteins to 
nitrocellulose membranes, the membrane was blocked for 30 min in PBS-0.05% 
Tween-20 supplemented with 5% non-fat dry milk. Signals were visualized with 
SuperSignal West chemiluminescent substrate (Thermo-Pierce). Western blot 
signal intensities were determined by density quantification using ImageJ 
software where appropriate. Protein concentrations were determined using the 
BCA method (Pierce). 
Immunoprecipitation of acetyl-lysine proteins. For immunoprecipitation of 
acetyl-lysine proteins and detection of NDUFA9 and AceCS2 acetylation, 500ug 
to 1mg of cardiac mitochondria was solubilized for 30 min on ice in 1% lauryl 
maltoside (Mitosciences) and centrifuged at 16,000 x g for 10min at 4°C to pellet 
debris and lipid membrane components. Anti-acetyl-lysine antibody (Cell 
Signaling) was loaded with the solubilized mitochondrial supernatant at a ratio of 
1:25 w/w and incubated overnight at 4°C with gentle agitation. Following 
incubation with the anti-acetyl-lysine antibody, the sample was incubated at 4°C 
with gentle agitation for an additional 2 hours with 7.5 µl Protein A agarose 
(Invitrogen) plus 7.5 µl Protein G agarose (Roche). Agarose was collected via a 1 
min centrifugation at 400 x g at 4°C on a desktop centrifuge and the unbound 
mitochondrial supernatant was carefully removed from above the agarose beads. 
The beads were washed 3 times for 5 min in 500 µl IP buffer containing 50 mM 
Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM EGTA, and 0.5% NP-40 at 4°C and then 
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incubated in 30 µl SDS sample loading buffer and boiled at 95°C for 5 min. The 
immunoprecipitated sample was then resolved on a 12% SDS-PAGE and 
processed for Western blotting. These methods were adapted from Ahn, et al. 
(69). 
Mitochondrial NAD+ and NADH measurements. NAM was excluded from MIB 
used to isolate mitochondria for NAD+ measurements as the enzyme 
nicotinamide phosphoribosyltransferase (Nampt) catalyzes the formation of 
NMN, an NAD+ precursor, from NAM. NAD(H) measurements were performed 
with a cycling assay according to the manufacturer’s instructions (Bioassay 
Systems). Briefly, NAD+ is extracted in the mitochondrial sample via addition of 
strong acid and then heated at 60°C to eliminate the presence of the reduced 
nucleotide (NADH). NADH is extracted in mitochondrial sample homogenate via 
addition of strong base and then heated at 60°C to eliminate the presence of the 
oxidized nucleotide (NAD+). The extractions are neutralized with the opposite 
extraction buffer and the dehydrogenase cycling assay is performed in which, in 
the presence of lactate, lactate dehydrogenase, diaphorase and MTT formazan 
reagent, the concentration of NAD+ or NADH present in the sample is 
proportional to the amount of reduced MTT formation which is colorimetrically 
detected with a plate reader at 562 nm (209, 210). Sample concentrations are 
determined via an NAD+ standard curve. The coenzyme concentration was 
normalized to the protein concentration of the sample.  
In vitro SIRT3 deacetylation assay. Two hundred microliters of 2 µg/ul Frataxin-
/- cardiac mitochondria frozen in 50mM Tris-Cl pH 7.4, 150mM NaCl were thawed 
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on ice and solubilized in 1% lauryl maltoside for 30 min on ice and centrifuged at 
16,000 x g for 10min at 4°C to pellet debris and lipid membrane components. 100 
µl of the soluble mitochondrial supernatant was mixed into 100 µl of 2x 
deacetylase buffer (50 mM Tris-Cl pH 8.0, 150 mM NaCl, 2 mM MgCl2, with or 
without 20 mM NAD+). Recombinant GST-tagged SIRT3 corresponding to amino 
acids 101-399 of human SIRT3 (Sigma) in 40 mM Tris-Cl pH 8.0, 240 mM NaCl, 
and 20% glycerol was added to 30 µl (30 µg) of the 1:1 mitochondrial protein : 2x 
deacetylase buffer mix in a 1.5ml tube. An appropriate amount of buffer 
containing only 40 mM Tris-Cl, 240 mM NaCl, and 20% glycerol was added to 
incubations lacking SIRT3 or less than 3 µg of SIRT3 to equalize the incubation 
volumes. The reactions were incubated for 4 hours at 37°C at 400rpm in an 
Eppendorf Thermomixer and briefly centrifuged every 30 min of incubation time 
to minimize reaction condensation. Following the incubation, the reactions were 
stopped upon addition of SDS loading buffer, boiled and processed for Western 
blotting as described above. 
Statistical Analysis. Statistical significance was determined using a two sample 
t-test assuming unequal variances. Any P value less than .05 was judged to be 
significant. 
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CHAPTER III: FATTY ACID OXIDATION IN THE FRATAXIN-DEFICIENT 
HEART 
Introduction 
The mammalian heart primarily utilizes fatty acids as its preferred fuel 
substrate, generating as much as 70% of the ATP for contraction from the β-
oxidation of fatty acids (36). Although the heart is capable of shifting its fuel 
substrate during acute states of fasting, exercise, or β-adrenergic stimulation, 
prolonged alterations in myocardial fuel utilization is associated with the evolution 
of heart failure (37). Furthermore, individuals harboring genetic defects at any 
step of the β-oxidation spiral are often intolerant to fasting and cold exposure and 
are susceptible to sudden cardiac arrest (211). Genetic ablation of the NAD+-
dependent deacetylase SIRT3 in mice causes accumulation of long-chain fatty 
acid species in serum and tissue, intolerance to cold exposure, and a marked 
inhibition of the β-oxidation enzyme LCAD (66), all symptoms which resemble 
clinical disorders of β-oxidation. The finding that hyperacetylation in the Frataxin-
deficient heart is caused, at least in part, by SIRT3 dysfunction, suggests that 
Frataxin deficiency may also reduce the capacity of the heart to oxidize fatty 
acids. Additionally, mitochondrial disorders of the respiratory chain are known to 
impair fat oxidation by redox state-mediated (low NAD/NADH) inhibition of 
multiple NAD+-dependent dehydrogenases of the oxidation spiral (38). Therefore, 
the finding that SIRT3 may be impaired and that lack of Frataxin causes 
deficiencies in multiple respiratory chain complexes both suggest that the 
Frataxin-deficient heart experiences impaired oxidation of fatty acids, which could 
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have important implications for the clinical management of cardiomyopathy. We 
sought to test this hypothesis using the muscle creatine kinase Cre (MCK-Cre, 
MCK-KO) conditional mouse model of Friedreich’s Ataxia. 
 
Results 
To test the hypothesis that fat metabolism is impaired in the Friedreich’s 
Ataxia heart, staining of wild-type and MCK-KO ventricular myocardium was 
performed with the fat-soluble dye Oil-Red-O. The 10 week-old WT mice show 
no evidence of lipid in cardiomyocytes. In contrast, 10-week old MCK-KO mice 
exhibit an accumulation of ectopic lipid droplets throughout cardiomyocytes 
(Figure 3.1A). This cardiomyocyte steatosis was not observed in every cell, 
indicating some cardiomyocytes are more susceptible to this phenotype than 
others, which could reflect different areas of disease progression throughout the 
heart or mosaicism of the conditional Cre expressing allele. Cellular lipid primarily 
takes two forms; either triglyceride or free (non-esterified) fatty acids. Extracting 
total lipid and subsequently assaying for triglyceride content revealed no 
difference in the total cardiac triglyceride content between WT and MCK-KO 
animals (Figure 3.1C). This indicated that the ectopic lipid in MCK-KO hearts is 
probably composed of non-esterified fatty acid species and likely unoxidized 
acylcarnitine species consistent with mitochondrial dysfunction (38, 212). 
Analysis of protein expression in whole heart homogenate revealed no difference 
in the expression of the key fatty acid oxidation nuclear receptor PPARα or its 
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 Figure 3.1 (A) Oil-Red-O staining of ventricular myocardium from wild-type and 
MCK-KO mice at 10 weeks of age. (B) β-oxidation and respiratory chain subunit 
protein expression in whole heart homogenate from WT and MCK-KO mice 
between 9 and 11 weeks of age (n=2-3/genotype, *P<.05) (C) Determination of 
cardiac triglyceride content in wild-type and MCK-KO mice between 9 and 10 
weeks of age. N.S. = not significant. 
 
downstream target genes LCAD or medium-chain acyl-CoA dehydrogenase 
(MCAD), but significantly decreased expression of respiratory chain complex II 
and III subunits SDHB and rieske protein, respectively (Figure 3.1B). 
SIRT3-/- mice exhibit a fatty acid oxidation impairment caused by failure to 
deacetylate lysine 42 of LCAD in the β-oxidation spiral (66). Consequently, LCAD 
becomes hyperacetylated, which can be directly shown via mass-spectrometry or 
indirectly by immunoprecipitation of mitochondrial acetyl-lysine-containing 
proteins and subsequently Western blotting for LCAD. Performing the indirect 
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analysis on cardiac mitochondrial protein indicates that, similar to the SIRT3-/- 
mitochondria, Frataxin-deficient cardiac mitochondria show hyperacetylation of 
the SIRT3 targets LCAD and AceCS2 (121) (Figure 3.2). Additionally, we found 
another enzyme of β-oxidation, MCAD, to be hyperacetylated in the Frataxin-/- 
mitochondria. Together, these data suggested that altered protein acetylation 
could underlie impairments in fat oxidation in the Frataxin-deficient-heart, but 
 
Figure 3.2 SIRT3 targets and enzymes of the fatty acid oxidation spiral are 
hyperacetylated the Frataxin-deficient heart. Mitochondrial acetyl-lysine 
containing protein were immunoprecipitated with an anti-acetyl-lysine containing 
antibody, resolved by SDS-PAGE and immunoblotted with antibodies raised 
against the mitochondrial proteins acetyl-CoA synthetase 2 (AceCS2), long-chain 
acyl-CoA dehydrogenase (LCAD), and medium-chain acyl-CoA dehydrogenase 
(MCAD).  
 
does not exclude the possibility that LCAD and MCAD are generally 
hyperacetylated at functionally irrelevant lysine residues. 
To directly assay the capacity of Frataxin-deficient cardiac mitochondria to 
oxidize fatty acids, we performed ex vivo analysis of fatty acid oxidation on 
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isolated cardiac mitochondria from WT and MCK-KO animals at 9-10 weeks of 
age using carbon-14 radiolabelled palmitate (66). Analysis of total 14C- palmitate 
oxidation rate over a 60 min incubation period normalized to mitochondrial 
protein content revealed that total flux through the fatty acid oxidation pathway is 
decreased by 35% (P< .05, n=6-8/genotype) in Frataxin-deficient cardiac 
mitochondria relative to control mitochondria (Figure 3.3A). Extracting the 14C-
acid soluble metabolite fraction which represents incompletely oxidized 
downstream products of β-oxidation such as acetyl-CoA, citrate, organic acids, 
and short chain fatty acids, indicated, paradoxically, no difference between 
control and Frataxin-deficient cardiac mitochondria (Figure 3.3B). Further 
analysis of complete oxidation to carbon dioxide (CO2) via capture of 14CO2 with 
hyamine hydroxide indicated a highly significant 68% decrease (P<.01, n=4-
5/genotype) in the rate of complete oxidation (Figure 3.3C). Taken together, 
these data show that Frataxin-deficient cardiac mitochondria suffer impaired β-
oxidation of fatty acids, but, interestingly, the rate of complete oxidation to carbon 
dioxide is decreased to a greater extent than fat oxidation, resulting in a net 
accumulation of unoxidized acid-soluble metabolites as demonstrated by the 
unchanged 14C signal in the acid-soluble metabolite fraction (Figure 3.4). 
 
Discussion 
These data demonstrate that Frataxin-deficient cardiac mitochondria 
suffer impaired oxidation of fatty acids despite no change in the expression of 
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key fat oxidation enzymes, which suggests the impairment may be 
mechanistically related to protein post-translational regulation and/or metabolite 
  
 
Figure 3.3 (A-C) Impaired fat oxidation, but accumulation of acid-soluble 
metabolites in Frataxin-deficient cardiac mitochondria. Isolated cardiac 
mitochondrial were incubated in the presence of carbon 14 radiolabelled 
palmitate and buffer supplemented with endogenous metabolites necessary for 
oxidation in vitro (see Materials & Methods) for 1 hour at 37°C. Following the 
incubation, perchloric acid was added which precipitates unoxidized fatty acid 
(A), maintains acid soluble metabolites (acetyl-CoA, organic acids) in solution 
(B), and liberates CO2 which can be captured with hyamine hydroxide-saturated 
filter paper (C). All three parameters were measured via liquid scintillation 
counting. (n=4-8/genotype, *P<.05, **P<.01.) 
 
feedback inhibition. Consistent with these explanations are data demonstrating 
that Fxn-/- mitochondria show hyperacetylation of the β-oxidation enzymes LCAD 
and MCAD (Figure 4.2) and data presented in Chapter III demonstrating a 
markedly decreased mitochondrial NAD+/NADH ratio. In order to convincingly 
prove that altered fat oxidation is caused by protein hyperacetylation, it is 
necessary to identify the functionally relevant acetyl-lysine residues on most, if 
not all, the enzymes involved in fat oxidation and also generate site-specific 
antibodies recognizing those relevant lysines and demonstrating that they are 
either hyperacetylated or deacetylated; whichever condition is associated with 
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decreased activity of the enzyme. Thus, although protein hyperacetylation is 
associated with impaired fat oxidation in Frataxin-deficient mitochondria, it does 
not illustrate a causal relationship. 
 
 
Figure 3.4 Schematic summarizing the experimentally determined fate of fatty 
acid-derived carbon in Frataxin-deficient cardiac mitochondria. 
 
The finding that Fxn-/- mitochondria experience an accumulation of acid-
soluble metabolites during substrate oxidation is very intriguing from the 
perspective of fundamental biochemistry. An accumulation of intermediary 
metabolites coupled with a dramatic reduction in the generation of CO2 reflects a 
metabolic block in the first span of the TCA cycle. Consistent with these findings, 
cardiac Frataxin-deficiency is known to impair the activity of mitochondrial 
aconitase by 80-90% in human patients(18, 213) and 70-74% in animal models 
(15). Frataxin directly regulates aconitase by converting its iron-sulfur cluster 
from the inactive [3Fe-4S]1+ form to the active, [4Fe-4S]2+ form in a citrate-
dependent manner (16). Thus, assuming an oxidative mode of carbon utilization 
in cardiac mitochondria, the acid-soluble metabolites which have a high likelihood 
of accumulating are those directly upstream of aconitase in the TCA cycle, or 
citrate and acetyl-CoA. Future measurement of cardiac citrate and acetyl-CoA is 
warranted. Because acetyl-CoA is required for lysine acetylation, this data 
suggests than an accumulation of mitochondrial acetyl-CoA could be associated 
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with a dramatic increase in mitochondrial protein acetylation. Therefore, these 
findings led to the testing of this hypothesis in the following chapter. 
 
Materials and Methods 
Conditional knockout mouse breeding and genotyping. Wild-type and MCK- 
conditional knockout animals were bred and genotyped as described previously 
(15, 59). The primers used to detect the presence of exon 4 for genotyping were 
5’-CTGTTTACCATGGCTGAGATCTC-3’ and 5’-
CCAAGGATATAACAGACACCATT-3’ which generates a 500 bp product. The 
primers used to detect the presence of the Cre transgene were 5’-
CCGGTCGATGCAACGAGTGAT-3’ and 5’-CAAAGAGTCAT CCTTAGCGCC-3’, 
which generate a 790 bp band. Mice that are genotyped as FrdaL3/Δ, Cre+ 
represent the conditional knockout animals. 
Mouse tissue preparation. For the isolation of whole heart homogenate, 
animals were sacrificed by CO2 asphyxiation and the tissue was immediately 
excised, washed and minced in cold phosphate-buffered saline. The tissue was 
then placed in 1-2 ml of ice-cold complete RIPA buffer containing an EDTA-free 
protease inhibitor cocktail (Roche product #05056489001), 10 mM nicotinamide 
(NAM) and 200 nM Trichostatin A as deacetylase inhibitors. The tissues were 
then homogenized with at least 10 passes of a motor-driven Potter-Elvehjem 
homogenizer at high speed. The whole tissue homogenates were then 
transferred to 1.5 ml tubes and spun at 17,000 x g for 10 min at 4°C in a desktop 
centrifuge to pellet membranes and tissue debris. The supernatant was saved 
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and immediately frozen on dry-ice and stored at -80°C for later protein 
quantification and Western blotting.  
Tissue processing and Oil-Red-O (ORO) stain. Hearts were immediately 
excised and washed in cold PBS to remove blood. Hearts were fixed in 4% 
paraformaldehyde (PFA) with gentle shaking overnight at 4°C. Fixed tissue was 
removed from PFA and gently dabbed with a paper towel to absorb excess PFA. 
The tissue was then placed in a conical tube containing a 30% solution of 
sucrose in PBS at 4°C until the tissue fell to the bottom of the tube. Tissue was 
removed from the sucrose solution and gently dabbed with a paper towel to 
absorb excess sucrose. The tissue was then embedded in OCT (Tissue-Tek) 
medium, frozen in liquid nitrogen-cooled isopentane, and stored at -80°C until 
sectioning. After temperature equilibration in the cryostat, 10 micron tissue 
sections were cut onto positively charged slides. The tissue-containing slides 
were then placed in cold PBS for 3 min to remove excess OCT medium and then 
re-fixed in ice-cold 10% neutral-buffered formalin (NBF) for 3 min. The NBF was 
gently removed from the slide, which was then placed back in cold PBS for 1 min 
to rinse off excess NBF. The tissue was then placed in 100% propylene glycol 
(Sigma) for 3 min to avoid carryover of water into the ORO stain. The tissue was 
then stained in pre-warmed 0.5% ORO in propylene glycol for 30 min in a 60°C 
oven. Tissue was then differentiated in 85% propylene glycol for 2 min at room 
temperature followed by 2 rinses in distilled water. Slides were then quickly 
immersed in Gill’s Hematoxylin (Polysciences, Gold Standard Series #3) for 2-3 
seconds and then immediately placed in running tap water for 3-4 min. Following 
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the tap water rinse, the slides were placed back in distilled water before being 
mounted with coverslips and an aqueous mounting medium. 
Cardiac triglyceride extraction and quantification. Tissue triglyceride 
extraction was performed using a modified Folch procedure substituting 
dichloromethane for chloroform (214). After evaporation of the organic phase, 
extracted triglycerides were resuspended in 100 µl of 1% Triton X-100 in 
isopropanol, briefly vortexed and incubated in an Eppendorf thermomixer for 5 
min at 60°C and 1000 rpm to improve resolubilization of triglyceride. 2 µl of the 
re-solubilized sample was used for triglyceride quantification with the Infinity 
Triglyceride Reagent (Thermo) according to the manufacturer’s instructions. 
Immunoprecipitation of mitochondrial acetyl-lysine proteins. Reverse 
immunoprecipitation of acetyl-lysine containing mitochondrial proteins was 
performed as described previously (185). 
Antibodies and Western Blotting. Antibodies used in this study include anti-
acetyl-lysine (Immunechem), anti-acetyl-lysine (Cell Signaling),anti- PPARα 
(Novus Biologicals), anti-LCAD (Abnova), anti-MCAD, anti-aconitase, anti-
complex II 30 kDa subunit, anti-NDUFA9, and anti-complex III Rieske protein 
(Mitosciences/Abcam), anti-SIRT3 D22A3, anti-VDAC D73D12, and anti-
Hexokinase II (Cell Signaling), anti-Gapdh (Sigma). Following transfer of the 
SDS-PAGE gel proteins to nitrocellulose membranes, the membrane was 
blocked for 45 min in PBS-0.05% Tween-20 supplemented with 5% non-fat dry 
milk. Signals were visualized with SuperSignal West chemiluminescent substrate 
(Thermo-Pierce). Western blot signal intensities were determined by density 
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quantification using ImageJ software where appropriate. Protein concentrations 
were determined using the BCA method (Pierce). 
Ex vivo measurement of fatty acid oxidation. Flux through the fatty acid 
oxidation pathway in isolated cardiac mitochondria was measured following the 
method of Hirschey, et al. with one additional step to derive the fat oxidation rate 
from the amount of unoxidized 1-14C palmitate (66) (also available at Protocol 
Exchange, http://www.nature.com/protocolexchange). After removing the acid-
soluble supernatant from the reaction tube for scintillation counting, the 
remaining supernatant (approximately 200 µl) was discarded and residual acid 
was evaporated for 5 min in a speedvac. Following evaporation, unoxidized 1-
14C palmitate was extracted by incubating the acid-insoluble precipitate in 400 µl 
of 2:1 dichloromethane: methanol for 30 min at room temperature on a nutator. 
Then 200 µl of this extract was added to 4 ml of scintillation cocktail and counted. 
This extraction method consistently achieved greater than 97% recovery of 
unoxidized, acid-insoluble 1-14C palmitate. The rate of oxidation was then derived 
by subtracting the counts of extracted 1-14C palmitate from the total counts of 
reaction input and dividing by reaction incubation time. 
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CHAPTER IV: WIDESPREAD AND ENZYME-INDEPENDENT Nε-
ACETYLATION AND Nε-SUCCINYLATION OF MITOCHONDRIAL PROTEINS 
VIA SPECIFIC BASE CATALYSIS  
Abstract 
Alterations in mitochondrial protein acetylation are implicated in the 
pathophysiology of diabetes, the metabolic syndrome, mitochondrial disorders, 
and cancer. However, the mechanisms initiating protein acetylation in 
mitochondria remain unknown. Here, by reproducing the physiologic pH and 
acetyl-CoA concentration of the mitochondrial matrix in vitro, we demonstrate 
dose- and time-dependent, but enzyme-independent Nε-acetylation of 
mitochondrial proteins that is reversed by the SIRT3 deacetylase. In a similar 
manner, succinyl-CoA induces non-enzymatic Nε-succinylation. These data 
suggest that protein acylation in mitochondria may be a form of chemical damage 
facilitated by the alkaline pH and high concentrations of reactive acyl-CoAs 
present in the mitochondrial matrix, and that SIRT3 evolved to mitigate the 
selectively inhibitory effects that non-enzymatic acetylation has on oxidative 
processes, especially during states of increased acetyl-CoA utilization such as 
fasting and caloric restriction. These findings may hold implications for the 
evolutionary roles that other sirtuin family members have in the maintenance of 
metabolic health and lifespan. 
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Introduction 
In Chapter II it was demonstrated that the Frataxin-/- heart exhibits 
progressive hyperacetylation of mitochondrial proteins which is caused, at least 
in part, by a deficiency of the SIRT3 deacetylase. Directly comparing cardiac 
mitochondria from SIRT3-/- animals to Frataxin-/- animals via Western blot 
indicated that many hyperacetylated proteins are shared between the two 
conditions (Chapter II, Figure 2.7). However, in every instance of a shared band, 
the degree of hyperacetylation was greater in the Fxn-/- mitochondria. This 
observation lead supports the conclusion that complete absence of SIRT3 cannot 
account for the degree of acetylation observed in the Fxn-/- heart, and therefore 
there must be additional mechanisms, independent of SIRT3-dysfunction, that 
contribute to the hyperacetylation phenotype in these animals. This led us to 
initiate the following study which sought to test alternative mechanisms for 
mitochondrial protein hyperacetylation. 
Understanding the molecular events underlying metabolic adaptations to 
fuel availability represents a fundamental challenge in cell biology with 
implications for the treatment of many diseases, such as cardiovascular disease, 
diabetes, and cancer. These cellular adaptations are often orchestrated through 
post-translational modification (PTM) of proteins, which can rapidly alter protein 
function to suit the metabolic circumstances. Recent proteomic investigations 
have revealed that one PTM, lysine acetylation (Nε-acetylation), is widespread in 
bacterial and eukaryotic cells and likely has conserved adaptive and regulatory 
roles in diverse cellular processes (64, 123, 124, 142, 215). As the hub of cellular 
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metabolism and the primary site of acetyl-CoA utilization, mitochondria and the 
proteins within it are highly acetylated. The most recent survey of the 
mitochondrial protein acetylome indicates that over 65% of mitochondrial proteins 
are acetylated at over 2,100 sites (216). Focused studies show that Nε-
acetylation influences multiple processes of intermediary metabolism including 
fatty acid oxidation, the tricarboxylic acid cycle, oxidative phosphorylation and the 
urea cycle, among others (66, 69, 217, 218). Moreover, alterations in 
mitochondrial protein acetylation or an inability to dispose of excess 
mitochondrial acetyl-CoA are implicated in the pathophysiology of diabetes, the 
metabolic syndrome, and mitochondrial disorders such as Friedreich’s Ataxia 
(185, 219-221). Despite the regulatory capacity and pervasive nature of 
acetylation in mitochondria, the mechanism(s) underlying acetyl-transfer in this 
organelle remain unknown.  
Evidence from other cellular acetylation events suggests that non-
enzymatic acetylation may occur in the conditions of the mitochondrial matrix. 
For example, members of the Gcn5-related N-acetyltransferase (GNAT) 
superfamily of enzymes employ a general base catalyst to deprotonate the 
positively charged ε-amino group of a lysine residue on the accepting protein 
(222-224). The deprotonated lysine then performs a nucleophilic attack on the 
carbonyl carbon in the acetyl group of acetyl-CoA, which displaces the thioester 
bond, leaving free –CoA and an Nε-acetyl-lysine. Predictably, mutating the 
catalytic base of GCN5 abolishes acetyl-transfer, but more importantly, the rate 
of acetyl-transfer to histone substrate can be near completely recovered in the 
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absence of enzyme merely by increasing the pH of the reaction buffer (224). 
Thus, chemical (non-enzymatic) acetylation of lysine residues is energetically 
favourable provided acetyl-CoA is present and the pH is greater than 7.0 – a 
reaction which is well-documented (224-228) and is properly accounted for 
during kinetic characterization of acetyltransferases (224). Remarkably, the 
mitochondrial matrix maintains a higher acetyl-CoA concentration and higher pH 
than any other cellular compartment. Steady state oxidation of carbon fuel 
generates between 0.1 and 1.5 millimolar concentrations of acetyl-CoA within 
mitochondria (229, 230), which is 3 to 50-fold higher than that of the whole cell 
according to current estimates in yeast (231) (Figure 4.1B). Additionally, due to 
the extrusion of H+ ions across the inner mitochondrial membrane to generate 
proton-motive force, the pH of the mitochondrial matrix is maintained at 7.9-8.0, 
which is 0.8 pH units higher than the next closest cellular compartment (cytosol, 
pH 7.2) (232). Although the ε-amino group of lysine has an intrinsic pKa of 10.5, 
it is well-established that local protein structure can promote marked decreases 
in amino acid pKa values via Coloumbic interactions with proximal charged 
residues (233) which, interestingly, are overrepresented among mitochondrial 
acetyl-lysine sequence motifs (234). Furthermore, non-enzymatic modification of 
lysine residues is known to occur in vivo (235) (Figure 4.1A). Taken together, 
these findings support the hypothesis that the chemical conditions of the 
mitochondrial matrix may uniquely facilitate non-enzymatic acetylation of 
proteins. 
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Results 
To test the hypothesis that mitochondrial Nε-acetylation occurs chemically, 
we incubated soluble liver mitochondrial protein with varying concentrations of 
acetate or acetyl-CoA at pH 8.0. After incubating mitochondrial protein in 50 mM 
acetate for 5 hours, there was no change in protein acetylation (Figure 4.2). In 
contrast, incubating mitochondrial protein with low mM concentrations of acetyl-
CoA generated a dose- and time-dependent increase in lysine acetylation (Figure 
4.1C-F). We reasoned that if a mitochondria-localized enzyme were responsible 
for this acetylation, then heating the mitochondrial extracts to near-boiling prior to 
incubating with acetyl-CoA would denature the enzyme thereby eliminating its 
acetyltransferase activity. In contrast, if the observed increase in acetylation were 
non-enzymatic, then protein denaturation would promote acetylation by 
increasing the number of solvent-accessible lysines available to react with acetyl-
CoA. Strikingly, and consistent with the latter hypothesis, our data show that pre-
boiling the mitochondrial extracts resulted in a dose- and time-dependent 
increase in lysine acetylation which was significantly greater relative to the native 
(unheated) state (Figure 4.1C-F). Incubating native and denatured cardiac 
mitochondrial protein with acetyl-CoA generated identical results (Figure 4.3). 
This acetylation increase was not caused by the denaturation process, as 
evinced by loss of acetylation while incubating denatured protein under acidic 
conditions and was equally robust in a non-primary amine buffer system (Figure 
4.4).  
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 Figure 4.1 Non-enzymatic Nε-acetylation in the chemical conditions of the 
mitochondrial matrix. (A) Non-enzymatic acetylation is chemically analogous to 
other endogenous non-enzymatic reactions like glycation and carbamylation. (B) 
Cartoon highlighting the unique chemical environment of the mitochondrial 
matrix. (C) Acetyl-CoA concentration-dependent increases in mitochondrial 
protein acetylation under native and denatured conditions. Mouse liver 
mitochondria were isolated, resuspended in buffer at pH 8.0 and 1.5 µg/µl, 
sonicated, and cleared by centrifugation. The extracts (30 µg) were incubated 
over a range of acetyl-CoA concentrations previously determined to occur in 
mitochondria (229, 230) (0.1-1.5 mM, 1 µl matrix volume/mg protein) for 6 hours 
at 37°C with gentle mixing. For denatured samples, mitochondrial extracts (30 
µg) were heated for 10 min at 95°C prior to addition of acetyl-CoA. Samples were 
separated by SDS-PAGE and immunoblotted with a polyclonal acetyl-lysine 
antibody and a monoclonal Complex III rieske protein antibody, which served as 
a loading control. (D) Quantification of densitometry data in (c) normalized to 
Complex III. The control reaction with the smaller arbitrary value was set to zero 
and the remaining data points transformed accordingly. AU; arbitrary units. (E) 
Time-dependent incorporation of acetyl-groups into native mitochondrial protein 
lysine residues. (F) Quantification of the densitometry data in (e) normalized to 
Complex III. In (c) and (e), the nitrocellulose membrane used for immunoblotting 
was stained with the non-specific protein marker Ponceau S as indicated to show 
equal loading. IB, immunoblot; kDa, kilodaltons. 
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 Figure 4.2 Free acetate does not influence the acetylation state of mitochondrial 
proteins. Incubating mitochondrial protein with millimolar concentrations of 
acetate has no effect on protein acetylation. Liver mitochondrial protein (30 µg) 
was prepared as described in materials and methods and incubated with the 
indicated concentrations of acetate at pH 8.0 for 5 hours at 37°C. Samples were 
resolved by SDS-PAGE and immunoblotted with a polyclonal acetyl-lysine 
antibody and a monoclonal succinate dehydrogenase subunit B antibody as a 
loading control. IB, immunoblot; SDHB, succinate dehydrogenase subunit B.  
 
Although the increase in Nε-acetylation in the denatured state showed that 
robust acetyl-transfer can occur in the absence of an enzyme in these conditions, 
it did not exclude the possibility of enzyme-mediated acetylation in the native 
state. Acetyltransferases in the GCN5 and MYST families are competitively 
inhibited by their product, coenzyme A (CoA) (236), and protein 
acetyltransferases outside the GCN5 and MYST families are predicted to 
undergo competitive inhibition owing to their structurally conserved CoA binding 
domains (223). Thus, if a protein acetyltransferase were responsible for acetyl-
transfer in the native state, it would likely be competitively inhibited in the 
presence of CoA. To test the hypothesis that acetyl-transfer is competitively 
inhibited by CoA, we incubated native mitochondrial protein with increasing 
concentrations of CoA while keeping the acetyl-CoA concentration constant at 
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1.5 mM. As shown in Figure 4.5A, increasing the concentration of CoA to double 
that of acetyl-CoA had no effect on the protein acetyl-transfer reaction. Thus, 
acetyl-transfer under native protein conditions is not competitively inhibited by 
CoA, and most likely occurs independently of CoA binding. 
 
Figure 4.3 Acetyl-CoA induced acetylation of cardiac mitochondrial proteins 
under native and denatured conditions. Cardiac mitochondrial protein (30 µg) 
was prepared as described in materials and methods and incubated in 1.5 mM 
acetyl-CoA for 0 or 9 hours under native or denatured conditions as indicated. 
Samples were resolved by SDS-PAGE and immunoblotted with a polyclonal 
acetyl-lysine antibody and a monoclonal complex III rieske protein antibody as a 
loading control. IB, immunoblot 
 
If protein acetylation in mitochondria is non-enzymatic, then incubating 
non-mitochondrial protein under the minimal chemical conditions of the 
mitochondrial matrix (pH 8.0, mM [acetyl-CoA]) should also induce protein 
acetylation. Incubating non-acetylated bovine serum albumin (BSA) for 9 hours in 
1.5 mM acetyl-CoA at pH 6 or 7 resulted in no, or minimal increases in protein 
acetylation. In contrast, incubating BSA at pH 8.0 induced a striking increase in  
88 
 
 Figure 4.4 Nε-acetylation of denatured mitochondrial proteins is not caused by 
the denaturation process and occurs equally well in a non-primary amine buffer. 
(A) Thirty micrograms of liver mitochondrial protein was denatured for 10 min at 
95°C followed by incubation at 37°C with the indicated concentrations of acetyl-
CoA at the indicated pH for 6 hours at 400 rpm on an Eppendorf Thermomixer. 
Samples were separated by SDS-PAGE followed by immunoblotting with a 
polyclonal acetyl-lysine antibody as described in materials and methods. Prior to 
the blocking step, the membrane containing transferred protein was imaged with 
the non-specific protein stain Ponceau S as seen below. IB, immunoblot. (B) 
Acetylation occurs equally well in a non-primary amine buffer. Liver mitochondrial 
protein were prepared as described in materials and methods, only in 50 mM 
HEPES (pH 8.0), 150 mM NaCl and incubated with the indicated concentrations 
of acetyl-CoA.  
 
lysine acetylation (Figure 4.5B), which was further increased at higher pH and 
was directly proportional the concentration of hydroxide ions (Figure 4.6). 
Recently, lysine succinylation was identified on mitochondrial and bacterial 
proteins, but a mechanism responsible for succinyl-transfer was not identified 
(134, 237). Using a validated succinyl-lysine antibody, we confirmed via Western 
blot that there are many succinylated proteins in mouse liver mitochondrial 
extracts (Figure 4.7A). Like acetyl-CoA, succinyl-CoA is an inherently reactive 
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 Figure 4.5 The acetyl-transfer mechanism is not competitively inhibited by CoA 
and its rate is directly proportional to hydroxide ion concentration. (A) Coenzyme 
A (CoA) does not competitively inhibit the observed acetyl-transfer reaction. 
Native mitochondrial protein was incubated with the indicated concentrations of 
CoA or acetyl-CoA at pH 8.0 for 6 hours and processed for immunoblotting as in 
Fig 1C. Complex III rieske protein was used as a loading control. (B) The 
chemical conditions of the mitochondrial matrix (pH 8.0, mM [acetyl-CoA]) are 
necessary and sufficient to induce widespread acetylation of a non-mitochondrial 
protein (bovine serum albumin, BSA) under native conditions. BSA was 
incubated in the presence of 1.5 mM acetyl-CoA at pH 6.0, 7.0, or 8.0 as 
indicated for 9 hours. Samples were resolved by SDS-PAGE and processed for 
immunoblotting as in Figure 1c. (C) Lysine acetylation rate is directly proportional 
to the concentration of hydroxide ions, consistent with specific base catalysis. 
AU; arbitrary units (derived from densitometry data in supplementary Figure 5.6).  
 
short chain –CoA thioester that maintains steady-state concentrations in the 
millimolar range (0.1-0.6 mM) in the mitochondrial matrix (Figure 4.7B) (230). 
Accordingly, we hypothesized that incubating protein with succinyl-CoA at 
physiological pH would initiate non-enzymatic succinylation. Consistently, 
incubating non-acetylated BSA with 0.5 mM succinyl-CoA caused a pH-
dependent increase in lysine succinylation (Figure 4.7C). These results indicated 
that the pH and acyl-CoA concentrations of the mitochondrial matrix are sufficient 
to induce widespread and enzyme-independent protein lysine acylation. The 
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specific base-catalyzed nucleophilic acyl substitution mechanism predicted for 
these reactions is summarized in Figure 4.8. 
 
Figure 4.6 Nε-acetylation of non-mitochondrial protein occurs at physiological pH 
and increases in a pH-dependent manner. (A) Twenty micrograms of non-
acetylated bovine serum albumin (BSA) was incubated in 1 mM acetyl-CoA at 
the indicated pHs for 6 hours at 37°C as described in Materials and Methods. (B) 
Acetylation rate as a function of hydroxide concentration derived from 
densitometry of exposure above. The rate of Nε-acetylation is directly 
proportional to [OH-] prior to image saturation (< pH 9.0), consistent with specific 
base catalysis. Protein samples were separated by SDS-PAGE, transferred to 
nitrocellulose membrane, and immunoblotted with a polyclonal acetyl-lysine 
antibody as described in Materials and Methods. IB, immunoblot. 
 
The NAD+-dependent deacetylase SIRT3 regulates global acetylation of 
mitochondrial proteins (234, 238). Therefore, we hypothesized that SIRT3 target 
proteins would become hyperacetylated in the presence of acetyl-CoA at pH 8 
and that recombinant SIRT3 would mitigate the acetyl-CoA-induced increase in 
mitochondrial protein acetylation. Immunoprecipitation and Western blotting of 
acetylated mitochondrial proteins after incubation with acetyl-CoA showed that 
the SIRT3 targets LCAD and NDUFA9 (66, 238) were hyperacetylated (Figure 
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 Figure 4.7 Protein succinylation is abundant within mitochondria and also occurs 
non-enzymatically at physiological pH. (A) Fractionation of mouse liver tissue into 
whole cell lysate (WCL), cytoplasm (cyto), and mitochondrial (mito) fractions 
followed by Western blotting with an anti-succinyl-lysine antibody. Gapdh and 
respiratory complex III rieske protein antibodies were used to confirm 
cytoplasmic and mitochondrial sub-fractions, respectively (B) Acetyl-CoA and 
succinyl-CoA are both inherently reactive –CoA thioesters. (C) The physiologic 
pH (8.0) and succinyl-CoA concentration (0.1-0.6 mM) (230) of the mitochondrial 
matrix are sufficient to induce lysine succinylation of protein under native 
conditions. Suc-lysine, succinylated-lysine. 
 
4.9A). Furthermore, addition of recombinant SIRT3 in the presence of NAD+ 
specifically reduced the acetyl-CoA induced increase in Nε-acetylation; an effect 
which was lost upon addition of the sirtuin inhibitor, nicotinamide (NAM) (Figure 
4.9B).  
These data suggest that the tendency of a mitochondrial protein to 
become acetylated by acetyl-CoA will be dependent upon the dissociation 
constants, or pKa’s, of the solvent-accessible lysine residues undergoing 
chemical acetylation. Although lysine residues have an intrinsic pKa of 10.5, 
residue pKas can be markedly altered via Coulombic interactions with proximally 
charged residues (239). Typically, a proximal negative charge will increase the 
pKa and a proximal positive charge will decrease the pKa of a lysine residue. A  
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Figure 4.8 Specific base-catalyzed nucleophilic acyl substitution acetyl-transfer 
mechanism. Cartoon illustrating the specific base catalysed acetyl-transfer 
mechanism. The alkaline environment of the mitochondrial matrix reflects an 
increased concentration of hydroxide ions (OH-) free to abstract protons from 
solvent-accessible lysine residues (1). The deprotonated lysine can then perform 
a nucleophilic attack on the terminal carbonyl carbon of acetyl-CoA (2). A 
putative tetrahedral intermediate is formed (3), which then collapses, displacing 
the thioester bond, and leaving an acetylated lysine, CoASH, and hydroxide (4). 
This mechanism was adapted from that of the GCN5 acetyltransferase, which 
employs a general base catalyst to deprotonate lysine residues and initiate 
acetyl-transfer (224). 
 
recent quantitative proteomics investigation catalogued all putative SIRT3 target 
acetyl-lysine residues as well as the magnitude of acetyl-lysine change in 
response to SIRT3 deletion (234). We hypothesized that putative SIRT3 target 
residues undergoing the greatest increases in acetylation in response to SIRT3 
deletion would have a greater number of proximal positively charged residues  
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 Figure 4.9 The SIRT3 deacetylase attenuates acetyl-CoA-induced acetylation of 
mitochondrial proteins. (A) Soluble liver mitochondrial extracts (120 µg) were 
incubated with or without 1.5 mM acetyl-CoA at pH 8.0 and 37°C for 4 hrs. 
Acetyl-lysine containing proteins were immunoprecipitated, followed by SDS-
PAGE and immunoblotting for the SIRT3 targets NDUFA9 and LCAD. IP, 
immunoprecipitation; Ac-K; acetyl-lysine. (B) Liver mitochondrial extracts (30 µg) 
were incubated at pH 8.0 with acetyl-CoA, recombinant glutathione S-transferase 
(GST) tagged human SIRT3, and a sirtuin inhibitor, nicotinamide (NAM), in the 
presence of NAD+ as indicated. Samples were resolved by SDS-PAGE and 
immunoblotted with a polyclonal acetyl-lysine antibody. A SIRT3 antibody was 
used to demonstrate the presence of recombinant (59 kDa) and endogenous (28 
kDa) SIRT3; A respiratory Complex III rieske protein antibody was used as a 
loading control. IB, immunoblot; kDa, kilodaltons; NAD+, nicotinamide adenine 
dinucleotide. 
 
than target residues with smaller increases in acetylation. Using the proteomic 
data in the aforementioned study, we compared the number of positively charged 
residues within 2 amino acids of the target acetyl-lysine between 40 of the sites 
undergoing the greatest statistically significant increases in acetylation in  
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 Figure 4.10 Mitochondrial protein acetylation sites undergoing the greatest 
acetylation increases in response to SIRT3 deletion have significantly more 
proximal positively charged residues, suggesting pKa perturbation. (A) 
Comparing the number of positively charged amino acids within 2 residues of the 
acetyl-lysine between acetyl-sites undergoing smaller statistically significant 
positive fold changes in response to SIRT3 deletion and those undergoing larger 
significant positive fold changes in response to SIRT3 deletion (*P<.05, Wilcoxon 
Rank Sums Test). (B) Relative occupancy of amino acids proximal to the 
acetylated site between the two groups. Positively charged residues are colored 
in blue and all others are black. The Y axis represents the total fraction of amino 
acid residues at the indicated position relative to the acetylated site. 
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response to SIRT3 deletion and 40 sites with lower statistically significant 
increases in acetylation with a fold change greater than 2. As shown in Figure 
4.10A, there were significantly (P<.05) more proximal positively charged amino 
acids in the set undergoing the greatest increase in acetylation in response to 
SIRT3 deletion, suggesting that local positively charged amino acids are lowering 
the pKa of the SIRT3 target residues, thereby increasing the likelihood of non-
enzymatic acetylation at physiological pH. Analysis of proximal amino acid 
abundance with ICE LOGO confirmed this finding (Figure 4.10B).  
 
Discussion 
These data suggest that, in contrast to enzyme-mediated acetylation 
present in the nucleus and cytosol where the pH and acetyl-CoA concentrations 
are relatively low, acetylation of proteins in mitochondria may be a slow, non-
enzymatic event uniquely facilitated by an alkaline environment and millimolar 
concentrations of acetyl-CoA. If this model holds true, then physiological and 
pathological metabolic states which induce prolonged increases in mitochondrial 
acetyl-CoA utilization would also promote hyperacetylation of mitochondrial 
proteins. Consistent with this prediction are data showing that fasting, caloric 
restriction, high fat diets, and chronic alcohol consumption all cause 
hyperacetylation of hepatic mitochondrial proteins (64, 123, 194, 220). Moreover, 
all are also associated with varying degrees of increased ketone body 
production, which is stimulated, in part, by excess acetyl-CoA in hepatic 
mitochondria (240-243). These findings strongly suggest that changes in the 
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mitochondrial concentration of acetyl-CoA during metabolic stress are a primary 
factor underlying altered protein acetylation in this organelle. 
According to our proposed model, tissue-specific differences in 
mitochondrial protein acetylation will be dictated by several different physiological 
factors, the most influential of which are the number of solvent-accessible lysine 
residues within the mitochondrial proteome and the steady-state concentration of 
acetyl-CoA. Although every tissue contains mitochondria, each tissue has a 
different mitochondrial proteome with respect to both the types of proteins and 
their abundance. Therefore, each tissue-specific mitochondrion will have a 
different number of solvent-accessible lysine residues available to chemically 
react with acetyl-CoA. Differences in mitochondrial proteomes also influence the 
capacity of a mitochondrion to both generate and consume acetyl-CoA. Thus, 
distinct tissues will likely have different steady-state concentrations of 
mitochondrial acetyl-CoA which can fluctuate in response to metabolic stress 
such as fasting and, therefore, could also influence the non-enzymatic 
acetylation rate. Aside from solvent-accessible lysines and acetyl-CoA 
concentration, we predict that the rate of protein turnover, SIRT3 expression 
level, and degree of uncoupling will also influence tissue-specific differences in 
mitochondrial protein acetylation.  
Recent studies indicate that the majority of acetylation sites identified in 
mitochondria may be non-functional. For example, among the eight acetylated 
lysines identified on the fatty acid oxidation enzyme long-chain acyl-CoA 
dehydrogenase (LCAD), only one acetylated site, lysine 42, altered enzyme 
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activity (66). Similarly, of the eleven acetylated lysines were identified on 
hydroxylmethylglutaryl CoA synthase 2, only 3 sites altered enzyme activity 
(195). Furthermore, this general trend was also observed for the mitochondrial 
enzymes acetyl-CoA synthetase 2, respiratory complexes I and II, manganese 
superoxide dismutase, isocitrate dehydrogenase 2, and malate dehydrogenase 2 
(69, 129, 206, 216, 217, 244). Interestingly, the functionally relevant acetyl-
lysines identified in these studies all decrease enzyme activity – an effect which 
is reversed via deacetylation mediated by the NAD+-dependent SIRT3 
deacetylase. Together, these studies suggest that only a fraction of mitochondrial 
acetyl-sites alter enzyme function and among those that do, the effect is 
consistently inhibitory. 
In the liver, increased mitochondrial utilization of acetyl-CoA during caloric 
restriction correlates with an increase in mitochondrial protein acetylation and a 
parallel increase in SIRT3 deacetylase expression (123, 216). Similarly, both 
fasting and high-fat diet stimulate increased mitochondrial protein acetylation with 
a concurrent increase in SIRT3 expression (64, 66, 220). These findings indicate 
that metabolic states causing increased mitochondrial protein acetylation also 
stimulate the expression of the SIRT3 deacetylase. Despite the general increase 
in mitochondrial protein acetylation during caloric restriction, a number of protein 
lysine residues exhibit markedly decreased acetylation, and these same lysines 
show increased acetylation when SIRT3 is deleted, indicating these select 
residues are likely targets of SIRT3-mediated deacetylation (216). These studies, 
taken together with the present findings, suggest a model in which metabolic 
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states demanding increased acetyl-CoA utilization, such as fasting or caloric 
restriction, cause the mitochondrial concentration of acetyl-CoA to rise, which, in 
turn, favours non-enzymatic acetylation of proteins. Whereas increased 
acetylation has minimal consequences on protein function at the majority of 
solvent-accessible lysine residues, a subset of acetylated lysines located near 
active sites or relevant protein folds, compromise enzyme function and overall 
metabolic efficiency (66, 195, 217). Under these stressful conditions, 
mitochondrial NAD+ levels rise (139) and SIRT3 deacetylase expression is 
induced (66, 218) in order to mitigate the selectively negative effects that 
acetylation confers on enzyme function and maintain metabolic efficiency. This 
proposed model is summarized in Figure 4.11. 
Importantly, these studies do not preclude the existence of a mitochondrial 
acetyltransferase. Rather, they question what physiologic role a mitochondrial 
acetyltransferase would play considering the chemical conditions of the 
mitochondrial matrix are more than sufficient to initiate non-enzymatic 
acetylation. Our findings demonstrating that the chemical conditions of the 
mitochondrial matrix promote widespread non-enzymatic protein acetylation, and 
previous findings showing that the majority of acetyl-sites are functionally benign 
(66, 69, 97, 195, 206, 216-218, 244), supports the concept that protein lysine 
acetylation in mitochondria is, at least in part, a non-specific chemical 
consequence of acetyl-CoA metabolism, analogous to non-enzymatic Nε-
glycation of haemoglobin in diabetes (235). Furthermore, these findings may also 
have implications for another post-translational modification recently identified on  
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Fig 4.11 Proposed model for chemical acetylation and SIRT3-mediated 
deacetylation of hepatic mitochondrial proteins. Metabolic states demanding 
increased mitochondrial acetyl-CoA utilization (i.e., fasting, CR, HFD) raise the 
mitochondrial concentration of acetyl-CoA which promotes non-enzymatic 
acetylation of solvent-accessible lysine residues. While much of the acetylation 
has no apparent consequences for protein/enzyme function (yellow circles), a 
subset of acetylated lysines cause functional impairments and decrease 
metabolic efficiency (red circles) (66, 97, 195, 206, 217). Under these same 
conditions (fasting, CR, HFD) SIRT3 deacetylase expression is induced and 
NAD+ levels rise (139) (fasting and CR only) to facilitate the deacetylation of 
functionally relevant acetyl-lysines and restore metabolic efficiency and 
homeostasis. The final reaction products are a deacetylated mitochondrial 
protein, 2-O-acetyl-adenosine diphosphate (ADP) ribose and nicotinamide 
(NAM). NAD+, nicotinamide adenine dinucleotide; CR, caloric restriction. 
 
mitochondrial proteins, lysine succinylation (134, 245). Like acetyl-CoA, succinyl-
CoA is also present in millimolar concentrations in mitochondria (229), 
suggesting that lysine succinylation may also be a chemical event. Interestingly, 
although mitochondria-localized SIRT5 is a weak deacetylase, it has efficient 
lysine desuccinylase and demalonylase activity in vitro (134). These findings 
suggest that, in addition to their important roles as metabolic intermediates, 
excess acyl-CoA intermediates act as unintentional chemical donors – a 
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hypothesis first proposed in 1982 by Kirschenbaum (246). Thus, SIRT3 and 
SIRT5 may have evolved to harness the fasting-induced rise in mitochondrial 
NAD+ (139) to minimize chemical acylation of protein caused by a concurrent 
increase in mitochondrial acyl-CoA utilization. Accordingly, and consistent with a 
recent review (238), we propose that the physiologic role of SIRT3 is as a quality 
control deacetylase which protects enzymes and proteins from chemical 
acetylation-induced impairment, especially during metabolic states that increase 
the mitochondrial pool of acetyl-CoA such as fasting, caloric restriction, or high-
fat, ketogenic diets. More broadly, considering chemical acetylation of proteins is 
a slow, nonetheless, energetically favourable reaction at physiological pH (224) 
(Figures 4.5 and 4.6), it is tempting to speculate that an unexpected number of 
cellular acetylation events may be chemical in nature and certain sirtuins may 
have evolved to protect organisms from unintentional, yet unavoidable chemical 
acylation of cellular proteins. 
 
Materials and Methods 
 
Mitochondrial Isolation. Fresh tissue (100-200mg) from wild-type mice on an 
inbred mixed C57BL/6J x 129/Sv-ter background was dissected and immediately 
immersed in ice-cold mitochondrial isolation buffer (MIB)(220mM mannitol, 70 
mM sucrose, 30 mM Tris-Cl (pH 7.4), 0.5 mM EGTA, and 0.1% BSA) 
supplemented with an EDTA-free protease inhibitor cocktail (Roche). Tissue was 
briefly minced with a razor blade and then homogenized in 1:5 w/v MIB with a 
2ml hand dounce homogenizer (Liver=10 passes, Heart=30 passes). 
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Mitochondria were then isolated using a standard differential centrifugation 
method as described previously (208), then resuspended and frozen in 50 mM 
Tris-Cl (pH 8.0 at 37°C), 150 mM NaCl or 50 mM HEPES (pH 8.0), 150mM NaCl 
at 1.50 µg/µl. When ready for use, mitochondria were thawed on ice, sonicated 
twice for 15 seconds each on ice, then cleared by centrifugation at 12,000 x g for 
10 min. Supernatants containing soluble mitochondrial protein were used for in 
vitro assays described below. Protein concentration was determined via the BCA 
method.  
In vitro incubation of mitochondrial protein and BSA with acetyl-CoA, 
succinyl-CoA and Western Blotting. A 48 mM solution of acetyl-CoA (Sigma) 
and a 100mM solution of sodium acetate were each made in 50 mM Tris-Cl, 150 
mM NaCl and adjusted to pH 8.0 at 37°C. Serial dilutions were made using 50 
mM Tris-Cl (pH 8.0 at 37°C), 150 mM NaCl as the diluent. Twenty microliters of 
the appropriate dilution was added to 20 µl of soluble mitochondrial protein (1.5 
µg/µl) in 50 mM Tris-Cl (pH 8.0 at 37°C), 150 mM NaCl to achieve the desired 
concentration of acetyl-CoA, or acetate. Total reaction volumes of 40 µl were 
incubated for 6 hours at 37°C at 400 rpm in an Eppendorf Thermomixer unless 
otherwise indicated. Reaction tubes were briefly centrifuged during the incubation 
to minimize condensation. For denatured protein experiments, soluble liver 
mitochondrial protein was heated at 95°C for 10 min and cooled on ice prior to 
the addition of acetyl-CoA. To test for competitive inhibition by CoA, a 12 mM 
solution of CoA (Sigma) was made in 50 mM Tris-Cl, 150 mM NaCl, and adjusted 
to pH 8.0 at 37°C. Dilutions of this CoA solution and acetyl-CoA solutions were 
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added to 30 µg of native mitochondrial protein in 50 mM Tris-Cl (pH 8.0 at 37°C), 
150 mM NaCl to achieve the desired concentrations in a final volume of 40 µl and 
then incubated for 6 hours at 37°C and 400rpm in an Eppendorf Thermomixer. 
For BSA experiments, 2 µg/µl solutions of non-acetylated, fatty-acid free BSA 
were made in 50 mM Tris-Cl, 150 mM NaCl and adjusted to either pH 6.0, 7.0, or 
8.0 at 37°C. Twenty microliters of each BSA solution was added to 20 µl of a 3 
mM solution of acetyl-CoA or 1 mM Succinyl-CoA adjusted to the same pH for 
final conditions of 40 µl total volume, 1.5 mM acetyl-CoA or 0.5 mM succinyl-
CoA, and 1µg/µl BSA in 50 mM Tris-Cl, 150mM NaCl at pH 6, 7, or 8. BSA 
reactions were incubated for 9 hours as described earlier, or 6 hours for succinyl-
CoA. Following the incubations, loading buffer was added and the samples were 
separated by SDS-PAGE, transferred to nitrocellulose membrane, blocked, and 
probed with a polyclonal acetyl-lysine antibody (Cell Signaling) or a polyclonal 
succinyl-lysine antibody (PTM Biolabs, Inc.), and monoclonal antibodies against 
succinate dehydrogenase iron-sulfur subunit (SDHB) and complex III rieske 
protein (UQCRFS1)(Mitosciences/Abcam). Signal was visualized with HRP-
conjugated polyclonal goat-anti-rabbit or goat-anti-mouse secondary antibodies 
and Supersignal Pico West chemiluminescent substrate (Pierce) and exposed to 
X-ray film. The pH was adjusted with an Oakton 1100 series digital pH meter or 
Corning pH meter 240 electrode calibrated to the same set of Fisher Scientific 
buffer solution standards. 
Immunoprecipitation. Mitochondrial protein extracts were prepared as 
described above and 120 µg per sample was incubated with or without 1.5 mM 
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acetyl-CoA at pH 8.0 and 37°C for 4 hrs. After incubation, the samples were 
diluted 1:10 in 50mM HEPES (pH 7.1), 150mM NaCl and 25 µl of acetyl-lysine 
antibody conjugated agarose beads (Immunechem) were added to each sample 
followed by incubation for 18 hrs at 4°C with gentle rocking. Beads were 
centrifuged at 400 x g for 1 min at 4°C and the supernatant decanted. The beads 
were washed 3 x 5 min in 250 µl of 50 mM Tris-Cl (pH 7.25), 150 mM NaCl, 1 
mM EDTA, 0.1% NP-40 and then boiled in loading buffer prior to SDS-PAGE. 
In vitro SIRT3 deacetylation assay. Soluble liver mitochondrial protein (30µg) 
was incubated in the following final reactions conditions: 48.4 mM Tris-Cl (pH 8.0 
at 30°C), 162 mM NaCl, 5.7% glycerol, 1.1 mM MgCl2, 5.7 mM NAD+, ± 7.2 mM 
Acetyl-CoA, ± 3µg GST-hSIRT3, ± 10 mM nicotinamide in a total volume of 70 µl. 
Reactions were incubated for 4 hrs at 30°C in an Eppendorf Thermomixer set to 
400 rpm. Reactions were briefly centrifuged at 2 hrs to minimize reaction 
condensation. Reactions were stopped with addition of loading buffer, and 
resolved on a 12% SDS-PAGE followed by immunoblotting with acetyl-lysine and 
complex III rieske protein antibodies as described earlier, and a polyclonal SIRT3 
antibody (Cell Signaling). 
Image Analysis. Integrated densitometries of Western blot exposures were 
calculated using Image J and a simple linear regression was performed on the 
plotted values (Figure 5.6). Cartoons and figures were generated using 
Chembiodraw Ultra 12.0 and Microsoft PowerPoint. 
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CHAPTER V: CONCLUSIONS  
Friedreich’s Ataxia (FRDA) is a fatal progressive mitochondrial disease 
caused by a pathological deficiency of the mitochondrial iron-binding protein 
Frataxin. Although the cause of FRDA is known, the disease has no cure, reliable 
treatment, or useful biomarker. Although the typical presenting symptom is 
ataxia, the most common cause of death among FRDA patients is heart failure, 
which represents a poorly understood, understudied, and poorly managed aspect 
of this devastating disease (247). Due to the general lack of clinical and basic 
knowledge regarding the cardiomyopathy in FRDA, many important questions 
remain. 
The majority of the pathological mechanisms operating in FRDA originate 
from mitochondrial dysfunction. However, few studies have focused on the 
mitochondrial and metabolic consequences of cardiac Frataxin deficiency. 
Recently, acetylation of mitochondrial proteins has been implicated in global 
nutrient sensing and the coordination of metabolic flux, which suggests altered 
protein acetylation could mediate pathological changes in mitochondrial 
metabolism (39). Understanding these potential metabolic changes could provide 
novel insight into the mechanisms underlying FRDA cardiomyopathy as well as 
potential metabolic biomarkers which could be used to study disease progression 
and/or response to treatments. This study has investigated the role of the post-
translational protein modification lysine acetylation in the evolution of 
cardiomyopathy in two conditional mouse models of FRDA. The data 
demonstrates a late-onset, progressive mitochondrial protein hyperacetylation in 
105 
 
the Frataxin-deficient heart. This novel disease phenotype develops concurrently 
with cardiac hypertrophy, is associated with a marked shift in mitochondrial redox 
state (NAD+/NADH) and parallels the previously reported progressive decline in 
mitochondrial iron-sulfur cluster dependent enzyme activity (15).  
The NAD+-dependent deacetylase SIRT3 regulates global acetylation of 
mitochondrial proteins and is particularly important in the maintenance of 
oxidative and intermediary metabolism (69, 125, 234). Mitochondrial protein 
hyperacetylation and loss of SIRT3 promotes the development of multiple 
pathologies including diabetes, the metabolic syndrome, heart failure, hearing 
loss, and cancer (127, 182, 203, 219, 220). These studies suggest that SIRT3-
deficiency and mitochondrial protein hyperacetylation are pathological in nature. 
Upon investigating the hypothesis that the dominant mitochondrial NAD+-
dependent deacetylase SIRT3 is deficient in FRDA, we found that SIRT3 targets 
are hyperacetylated, SIRT3 is excessively carbonylated, and recombinant SIRT3 
can reverse the protein hyperacetylation phenotype in vitro, all suggesting a 
defect in endogenous SIRT3 activity which could contribute to cardiomyopathy in 
FRDA. However, directly comparing SIRT3 knockout cardiac mitochondria to 
Frataxin KO cardiac mitochondria indicated that there must be mechanisms 
independent of SIRT3 deficiency contributing to the hyperacetylation phenotype 
in the Frataxin-deficient heart. Furthermore, ex vivo analysis of fatty acid 
oxidation in cardiac mitochondria revealed a defect in fat oxidation which should 
be confirmed through Positron Emission Tomography of FRDA patient hearts in 
vivo using radiolabelled substrate tracers. This analysis also revealed an 
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accumulation of intermediary metabolites, suggesting that mitochondrial acetyl-
CoA abundance could be mediating the hyperacetylation phenotype. This 
triggered the investigation of the basic mechanism underlying protein lysine 
acetylation in mitochondria, which is unknown.  
Protein acetylation in mitochondria is a relatively new field of investigation 
and many important basic questions remain. It is well-established that enzyme-
mediated lysine acetylation events have important roles in gene regulation and 
signaling events in cellular organisms. However, it is also known that the 
intracellular metabolite required for lysine acetylation, acetyl-CoA, is inherently 
reactive and capable of initiating non-enzymatic lysine acetylation events at 
physiological pH (224, 225, 227, 248). Surprisingly, despite the ubiquitous nature 
of acetyl-CoA and protein acetylation in living organisms, virtually no work has 
investigated the possibility that non-enzymatic lysine acetylation occurs and has 
functional consequences in biological systems.  
In vitro studies have shown that non-enzymatic acetylation is favored at 
alkaline pH and is acetyl-CoA concentration-dependent (224, 227). Thus, it was 
logical to hypothesize the mitochondrial matrix, which maintains a more alkaline 
pH and higher acetyl-CoA concentration than any other cellular compartment, 
might be one cellular environment in which non-enzymatic protein acetylation 
would be widespread (232). The present data strongly suggest that non-
enzymatic protein acetylation occurs in mitochondria and that the biological 
purpose of the NAD+-dependent deacetylase SIRT3 is to minimize its deleterious 
functional consequences. Furthermore, because SIRT5 is a mitochondria-
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localized desuccinylase, succinyl-CoA achieves high concentrations within 
mitochondria, and protein succinylation is abundant within mitochondria (Figure 
4.7), is logical to suggest that SIRT5 may have evolved to cope with the 
consequences of non-enzymatic succinylation. The common theme suggested 
by these findings is that many short chain acyl–CoA thioesters present within 
cells have the potential to non-enzymatically modify proteins, and thereby alter 
their function. This hypothesis was presciently proposed in 1982, but technology 
and reagents at the time were insufficient to properly investigate its possibility 
(246). Interestingly, mitochondria-localized SIRT4 currently lacks a defined 
enzymatic activity, but it is tempting to speculate that it serves to remove another 
short-chain acyl moiety from lysine residues, which likely occurred non-
enzymatically. These studies have provided a viable mechanism for protein 
acetylation in mitochondria which is related to the distinct chemical environment 
of the mitochondrial matrix, however these results do not exclude the possibility 
of an enzyme-mediated acetylation mechanism in mitochondria. It is, however, 
an indisputable empirical fact governed by the deterministic laws of chemistry 
that non-enzymatic acetylation of protein lysine residues will occur at 
physiological pH, and especially at mitochondrial pH, in the presence of acetyl-
CoA. 
Biology is inherently messy. There are numerous examples including 
error-prone DNA polymerases and accidental phosphorylation during glycogen 
synthesis. However, it is this messiness that is the driving force of evolutionary 
innovation (249). The data contained herein suggest that the NAD+-dependent 
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deacetylases SIRT3, SIRT5, and perhaps other Sirtuins, evolved to mitigate the 
deleterious metabolic consequences associated with non-enzymatic protein 
acylation caused by the inherent reactivity of -CoA thioesters, and thus may be 
considered damage control enzymes. 
A key implication of these findings is that acetyl-CoA, the most 
fundamental two-carbon unit of amino acid, fatty acid, and carbohydrate 
catabolism, may be, at least within mitochondria, non-enzymatically proteotoxic. 
Thus, perhaps, it is not surprising that genetic ablation of the major mitochondrial 
deacetylase SIRT3 is associated with multiple age-related pathologies including 
the metabolic syndrome, diabetes, cancer, and a general impairment in 
mitochondrial and metabolic homeostasis. This interpretation, although 
controversial, could perhaps, be integral to understanding why the Sirtuin family 
of deacetylases are believed to mediate the beneficial and healthful effects of 
caloric restriction and why they are protective in various metabolic diseases (71, 
114).  
How are these results relevant to the mitochondrial protein 
hyperacetylation phenotype and pathogenesis of cardiomyopathy in FRDA and 
perhaps other mitochondrial cardiomyopathies? Our results suggest that 
Frataxin-deficient cardiac mitochondria experience coordinate post-translational 
suppression of oxidative metabolism which is, in itself, pathological, because the 
heart is heavily dependent on oxidative processes for the ATP production 
necessary for cardiac contraction. However, the cause of this cannot be fully 
explained by SIRT3 impairment. This suggests a pathological process related to 
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the mechanism of acetylation in mitochondria, such as excessive acetyl-CoA 
within mitochondria, and/or additional impairments in, as yet, unidentified 
mechanisms of deacetylation. Previously, Vyas et al. reported that exogenous 
protein replacement therapy with Frataxin fused to the HIV transactivator of 
transcription (TAT-Frataxin) can partially rescue and extend lifespan in the NSE-
Cre Frataxin conditional knockout animals (59). Analyzing protein acetylation in 
preliminary data from NSE-Cre animals treated with TAT-Frataxin suggests an 
attenuation of protein acetylation in the Frataxin-deficient animals treated with 
TAT-Frataxin. This suggests that Frataxin protein replacement therapy can 
oppose the mitochondrial protein acetylation process, likely through indirect  
 
Figure 5.1 The effect of TAT-Frataxin protein replacement therapy on cardiac 
protein acetylation status. Western blot probing for acetyl-lysine residues on 
whole heart lysate (40 µg) derived from 25-30 day old NSE-Cre Frataxin 
conditional knockout animals or NSE-Cre animals treated with TAT-Frataxin for 3 
weeks. 
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mechanisms, and further supports TAT-Frataxin as a viable treatment option for 
FRDA. 
Future research should address if the mitochondrial protein 
hyperacetylation can be reduced through transgenic overexpression of SIRT3 
and if this intervention can improve cardiac function or extend lifespan in the 
conditional mouse models of FRDA. It is also possible that this intervention will 
have no salutary effects, because it will not serve to correct multiple iron-sulfur 
cluster defects. Future research should also focus on rigorous metabolomic 
characterization of both the Frataxin-deficient heart using animal models and 
serum samples from FRDA patients as well as cardiac positron emission 
tomography imaging of FRDA patients using substrate tracers. Together, this 
work will offer comprehensive understanding of the various mitochondrial and 
metabolic abnormalities in FRDA, which will further enhance our understanding 
of disease mechanisms and provide candidate biomarkers for monitoring disease 
progression and treatment response. 
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